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ABSTRACT 
THE ROLE OF NOTCH IN TH17 DIFFERENTATION 
SEPTEMBER 2013 
REEM SULEIMAN, B.S., UNIVERSITY OF KHARTOUM SUDAN 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by:  Professor Barbara A. Osborne 
Th17 cells are pro-inflammatory cells that are characterized by the production of their signature 
cytokine, IL-17. Although they are thought to have arisen to protect against extracellular bacteria 
and fungi they have been shown to mediate autoimmune diseases such as EAE and psoarisis. 
Notch protein is a cell-surface receptor that has been widely conserved among species. It plays 
an essential role in determining multiple cell fates. More recently, it has been implicated in 
regulating peripheral CD4
+ 
T-cell responses. In these studies, we report that blockade of Notch
signaling significantly down-regulates the production of IL-17 and associated cytokines in both 
mouse and human in-vitro polarized Th17 cells, suggesting an intrinsic requirement for Notch 
during Th17 differentiation in both species. We also present evidence, using promoter reporter 
assays, knockdown studies as well as chromatin immunoprecipitation, that IL-17 and RORt are 
direct transcriptional targets of Notch signaling in Th17 cells, with Notch 1 being the responsible 
Notch family member important in regulating the differentiation of human Th17 cells. In-vivo 
 `viii 
 
inhibition of Notch signaling reduced IL-17 production and Th17 mediated disease progression 
in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. In 
addition, by using Notch1 and Notch3 knockout mice, we have shown that Notch 3 is the Notch 
family member that is essential for murine Th17 differentiation. We have also investigated non-
canonical Notch signaling in Th17 cells by using CD4
+
 T-cells from CSL/RBP-Jk knockout 
mice. Based on data obtained, we have concluded that canonical Notch signaling is dispensable 
in Th17 responses. Thus, this study highlights the importance of different Notch family members 
in Th17 differentiation and indicates that selective targeted therapy against Notch may be an 
important tool to treat autoimmune disorders, including multiple sclerosis. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1. Overview of CD4+Tcells  
 
CD4
+
 T cells are a principle component of adaptive immune responses which 
are vital for the efficient eradication of infectious agents (Harrington et al., 2006). Upon 
meeting cognate antigen, naiive CD4 Th cells bind to complexes of foreign peptide and 
major histocompatibility complex class II (pMHCII) on antigen-presenting cells (APC) 
through their T cell antigen receptors (TCRs). Signals through the TCR and APC–
derived costimulatory molecules such as CD28 trigger the naive cells to divide and 
become effector cell lymphoblasts. Depending on the nature of cytokines produced by 
the innate immune system, these effector cells undergo a differentiation process that 
involves the expression of specific transcription factors that control the ability to 
produce a certain cytokine profile. This differentiation also involves the expression of 
homing receptors that facilitate the migration of effector cells to non-lymphoid sites of 
inflammation, where these cells produce their cytokines to aid in antigen clearance 
(Pepper et al., 2011). Mossman and Coffman (1996) showed that Th cells can 
differentiate into Th1 and Th2 cell. Since then and over the last couple of years, several 
new classes of Th cells have been discovered. These new lineages include T-reg, Th17, 
Th22, Th9 and Tfh cells.  
 
1.2. CD4+ T helper cell lineages 
2 
The major determinant for Th cell differentiation is the cytokine milieu at the 
time of antigen encounter, although the nature of cognate antigen and its affinity to the 
TCR as well as the available costimulants, many of which regulate initial cytokine 
production, can influence Th cell fate. It has been shown that the strength of TCR 
signaling regulates initial cytokine production since low concentrations of cognate 
peptide induce IL-4-independent IL-4 production during the first 24 h after T-cell 
engagement, whereas stimulation with high concentration of peptide suppresses ‘early’ 
IL-4 and induces IFN (Zhu and Paul, 2010). 
Transcription factors are critical for Th cell differentiation and cytokine 
production. Cell fate determination in each lineage requires at least two types of 
transcription factors, the master regulators and the signal transducer and activator of 
transcription (STAT) proteins. STAT proteins are activated by cytokines through post-
transcriptional modifications such as phosphorylation. Some STAT proteins are 
responsible for inducing the expression of master regulators. 
Th1 cells are characterized by the production of their signature cytokine, 
interferon- (IFN-). T-bet is regarded as the master regulator for Th1 cell 
differentiation. IFN- activates STAT1 which has been shown to induce T-bet 
expression during Th1 differentiation in vitro. Therefore, the IFN-/STAT1/T-bet/IFN- 
pathway serves as a powerful amplification mechanism for in for vitro Th1 
differentiation. T-bet potentiates expression of the ifng gene and upregulates the 
inducible chain of the IL-12 receptor (IL-12Rβ2) while suppressing Th2–associated 
factors. Induction of a competent IL-12 receptor on developing Th1 cells licenses IL-12 
3 
 
signaling through Stat 4, which further potentiates IFN- and upregulates T-bet 
expression. STAT4 activation by IL-12 is critical for Th1 responses both in vitro and in 
vivo (Zhu and Paul 2010; Weaver et al., 2006). 
IFN-γ augments the antigen-processing and antigen-presenting ability of APCs, 
stimulates IgG2a production by B cells, induces the expression of cytokines and 
chemokines required for the recruitment of myeloid cells to the site of inflammation, 
and increases the expression of Toll-like receptors, nitric oxide synthase, and phagocyte 
oxidase by macrophages. Th1 cells possess anti-viral properties and are important in 
cellular immunity, where they aid in the clearance of intracellular organisms (Lazarevic 
et al., 2011). Th1 cells have also been implicated in a vast array of autoimmune diseases 
ranging from multiple sclerosis to type I diabetes.  
Th2 effector differentiation depends on the presence of IL-4, STAT6 and is 
determined by expression of the GATA-3 transcription factor (Veldhoen et al., 2008). 
Th2 cells produce IL-4, IL-5 and IL-13. Like many T cell subsets, they can also produce 
IL-10. Th2 cells are mediators of humoral immunity and are important in the defense 
against parasites. They are also implicated in the pathogenesis of asthma and allergies. 
Th1 and Th2 cytokines are mutually exclusive and antagonistic to each other. 
Consequently, IFN-γ suppresses IL-4 production and IL-4 suppresses IFN-γ production. 
Th17 cells  are defined CD4
+
 effector T cells positive for the αβ T cell antigen 
receptor, which have high expression of the transcription factors RORα and RORγt, low 
expression of the transcription factors T-bet and GATA-3 and high surface expression 
of the chemokine receptor CCR6. They produce IL-17A-F and IL-22 cytokines, express 
the IL-23 surface receptor; and can produce the chemokine CCL20 (Flavell et al., 
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2010). Signaling through STAT3 has been shown to be essential for Th17 
differentiation (Yang et al., 2007). (Langrish et al., 2005; Park et al.,; Betteli et al., 
2006; Weaver et al., 2006; Harrington et al., 2006; Dong 2008). 
While IL-17 and IL-17F induce neutrophila, participate in immunity against 
certain bacterial and fungal infections, and are involved in the pathogenesis of multiple 
autoimmune diseases; IL-25(IL-17E) promotes eosinophila and appears to play 
important roles in Th2-mediated host defense against helminthic parasite infection as 
well as in exacerbating allergic airway diseases.(Reynolds et al., 2010). IL-23 signaling 
is not required for Th17 commitment and early IL-17 production but instead appears to 
be important for amplifying and/or stabilizing the Th17 phenotype (Dong 2008, Weaver 
et al., 2006). Nevertheless, McGeachy et al., 2009 found that IL-23 was necessary for 
the full differentiation of activated T cells into effector Th17 cells.  IL-23 also promotes 
T cell production of GM-CSF, a cytokine that is essential for the ability of Th17 cells to 
drive inflammation in the central nervous system (CNS). GM-CSF acts as a 
proinflammatory cytokine mainly by inducing the activation, maturation and 
differentiation of macrophages and dendritic cells, which are essential for the initiation 
and propagation of cell-mediated immune responses (McGeachey et al., 2011). 
In mice, Th17 cells arise from naive CD4+ T cells when activated in the 
presence of transforming growth factor-β (TGF-β) and IL-6. But, a study by Das et al., 
2009 shows that TGF- β does not directly promote Th17 cell differentiation but instead 
acts indirectly by blocking expression of the transcription factors STAT 4 and GATA-3, 
thus preventing Th1 and Th2 cell differentiation. IFN- and IL-4, the signature 
cytokines of Th1 and Th2 respectively, negatively regulate Th17 cells (Dong 2008). 
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The primary function of Th17 cells appears to be the clearance of pathogens that 
are not adequately handled by Th1 or Th2 cells, such as mediating immunity against 
extra-cellular bacteria and fungi (Dong 2008). IL -17 has diverse biological functions, 
but the best characterized relate to its proinflammatory effects. Specifically, IL-17 
recruits neutrophils via effects on granulopoiesis and CXC chemokine induction, acts 
on macrophages to promote their recruitment and survival and stimulates the production 
of proinflammatory cytokines and anti-microbial peptides from a variety of immune and 
non-immune cells. However, Th17 cells are potent inducers of tissue inflammation and 
have been associated with the pathogenesis of many experimental autoimmune diseases 
and human inflammatory conditions, including Crohn’s disease, systemic lupus 
erythematosus (SLE), rheumatoid arthritis and psoriasis (Kebir et al., 2007; Kuchroo et 
al., 2009).  
The AHR is a ligand-activated transcription factor from the Per-Arnt-Sim (PAS) 
superfamily of proteins. AHR has been studied as a receptor for environmental 
contaminants and as a mediator of chemical toxicity (Stevens et al., 2009). Recently, it 
has been found that AHR is a regulator of Treg and Th17 cell differentiation in mice. 
AHR activation by its ligand 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induces functional 
Treg cells that suppresses experimental autoimmune encephalomyelitis while AHR 
activation by 6-formylindolo (3, 2-b]carbazole interfered with Treg cell development, 
boosted Th17 cell differentiation and increased the severity of experimental 
autoimmune encephalomyelitis in mice. Thus, AHR regulates both Treg and Th17 cell 
differentiation in a ligand-specific fashion (Quintana et al., 2008).  
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Human Th17 cells are currently defined as cells that produce IL-17A and F, but 
not IFN-γ or IL-4. Th17 cells are also capable of producing tumour necrosis factor 
(TNF)-a, IL-6, IL-22, as well as IL-21 and IL-26. They express CCR4, CCR6 and IL-
23R, but not CXCR3. In addition CD161, the human orthologue of NK1•1, is associated 
with human Th17 cells. 
CD4
+
 regulatory T cells (Treg cells) are part of a regulatory mechanism that 
seeks to keep in check an overactive or dysregulated helper T cell response that may 
result in immune-mediated damage to the host. (O’ Garra et al., 2011). Naturally 
occurring Treg cells occur in the thymus, however, in the presence of TGF-Β, naiive T 
cells in the periphery can commit to the T-reg lineage, these cells are called iTreg 
(inducible Treg cells). Treg cell differentiation and function are driven by the 
transcription factor Foxp3. Mice carrying a mutant Foxp3 show impaired Treg cell 
activity and succumb to a fatal lymphoproliferative disorder, which can be prevented by 
the transgenic expression of wild-type Foxp3 
+
 Treg cells. 
Treg cell development is closely related to the generation of IL-17-producing T 
cells (Th17). Large amounts of TGF-β in the absence of inflammatory mediators will 
result in the development of Foxp3+ Treg cells, whereas lower concentrations of TGF-β 
in the presence of inflammatory mediators such as IL-6, IL-1 and IL-23 produced in the 
context of infection mediates the development of Th17 cells (Zhou et al., 2008). 
Follicular helper T (Tfh) cells reside in B cell follicles and are essential for the 
generation of high-affinity isotype switched antibodies and B cell memory (Stockinger 
et al., 2010).They are also important for the formation and maintenance of germinal 
7 
 
centers (GC). Tfh cells are characterized by the production of IL-2I, BCL6 is the unique 
transcription factor required for their differentiation. 
Th9 cells constitute a distinct population of helper–effector T cells that promote 
tissue inflammation and are derived in culture with a combination of TGF-β and IL-4 
(Veldhoen et al., 2008). These cells are related to Th2 cells in that they require STAT6 
and GATA-3 for development, but they have lower expression of Th2 cytokines. PU.1 
has been identified as the transcription factor that induces the Th9 phenotype by 
promoting the expression of IL-9 and proallergic chemokines. (Chang et al., 2010). IL-9 
is a pleiotropic cytokine with high expression in the lungs of asthmatic patients. In lung 
physiology, it has been proposed to induce mucous production, goblet cell hyperplasia 
and other features of airway remodeling. IL-9 is also involved in protective immunity to 
helminth infections, as indicated by enhanced kinetics of worm expulsion in IL-9 
transgenic mice and susceptibility to helminth infection upon IL-9 depletion (Wilhelm 
et al., 2011). 
IL-9-induced cell activation is mediated by a specific IL-9 receptor chain that 
forms a heterodimeric receptor with the common gamma chain (c) .Activating either 
STAT5, or STAT1 and STAT3, is required for IL-9-induced proliferation ( Li and 
Rostami 2010). 
Th22 cells are characterized by the production of IL-22 and have been found in 
humans but so far not in mice. Th17 cells are major producers of IL-22 in mice and 
RORt, which controls the generation of  Th17 cells, also seems critical for IL-22 
production (Trifari et al., 2009). IL-22 can act synergistically or additively with IL-17A, 
IL-17F or tumor necrosis factor (TNF) to promote the expression of many of the genes 
8 
 
that encode molecules involved in host defense in the skin, airway or intestine 
(Sonnenberg et al., 2011).A substantial proportion of Th22 cells recognize lipid 
antigens presented by CD1a expressed on Langerhan’s cells, some dermal DCs and 
macrophages. Tumor necrosis factor and IL-6 favor the development of Th22 cells from 
naive cells in vitro (O’Garra 2011). It has been found to have critical roles in regulating 
host defense, tissue homeostasis and inflammation, in particular at barrier surfaces. 
 
1.3. T helper cell plasticity 
 
T-helper cell lineage commitment was originally viewed as a unidirectional 
process with nonreversible terminal differentiation of cells. With the discovery of new 
T-helper cell lineages, it has been recognized that the commitment of T-helper cell 
lineage is more plastic than previously appreciated and several modes of plasticity of T 
cell subsets have recently been described (Zhou et al., 2009, Murphy et al., 2010). 
Th17 and iTreg cells show effector differentiation plasticity. TGF-β induces 
both Foxp3 and RORγt in naive T cells, but Foxp3 is dominant and antagonizes RORγt 
function unless IL-6 is present. Thus, an inflammatory environment tilts the balance 
between iTreg and Th17 differentiation (Yang et al., 2008) 
Although Th17 is a distinct lineage, it has been shown that fully committed 
Th17 cells can revert and adopt a Th1 phenotype in the absence of Th17 polarizing 
cytokines (Guangpu et al., 2008). Acquisition of IFN-γ–producing potential by Th17 
cells, particularly the simultaneous production of IL-17 and IFN-γ, is a common 
occurrence, especially in vivo. Th17 cells can even extinguish production of their 
9 
cytokine signature, becoming selective IFN-γ producers (O’ Shea 2010). TGF-β, a 
cytokine with a wide range of functions in the immune system, could alter Th2 cells to 
the extent that they lost their previous characteristics, including expression of GATA-3 
and the ‘signature’ cytokines IL-4, IL-5 and IL-13, and ‘switch on’ IL-9 (Veldhoen et 
al.,  2008 , O’ Shea 2010). 
T-cell plasticity has important implications in the treatment of Th17 mediated 
diseases, since any manipulation of cytokine concentrations can cause the Th17 lineage 
to switch production to an alternative cytokine which could potentially mediate 
different effects than those initially seen. 
1.4 Notch 
“If one was asked to choose the single, most important genetic variation 
concerned with the expression of the genome during embryogenesis in Drosphila 
melogonaster, the answer would have to be the Notch locus.”(Ted Wright, 1970). So 
begins the first review to emphasize Notch and today, some 42 years later and with the 
explosion of data regarding Notch biology, one could say with certainty that Notch has 
not just lived up to that inspiring sentence but with the discovery of the full extent of its 
effects throughout the animal kingdom and man, has actually surpassed it. 
Notch is a transmembrane molecular receptor that is widely conserved among 
species. It was first discovered in Drosophilla melanogaster, where loss of one of two 
copies of the gene led to the appearance of Notches at the wing margins, giving rise to 
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the name “Notch”. Notch signals influence a wide spectrum of cell fate decisions, both 
during development and in the adult organism.  
Mammals have four Notch receptors (Notch 1, 2, 3 &4) and five ligands, Delta-
like 1, 3 &4(DLL1, 3 and 4) and Jagged 1& 2(J1 &J2) (Osborne et al. 2006; Bray 
2006). Notch proteins are receptors for ligands of the DSL family (Delta-like/Jagged in 
mammals, Delta/Serrate in Drosophila melanogaster, Lag-2 in Caenorhabditis elegans). 
Notch signaling was first implicated in T cell activation when it was discovered that 
intracellular Notch1 was upregulated in T cells upon TCR stimulation (Palaga et al., 
2003; Adler et al., 2003).  In the immune system, Notch has been shown to favor the 
development of the T cell lineage rather than B cell lineage. αβ T cell development 
requires continuous Notch signaling up to the DN3 stage, where cells have to pass a 
critical checkpoint known as β-selection (Wolfer et al., 2002). Another well-
characterized role for Notch signaling in the lymphoid system involves the specification 
of marginal zone (MZ) versus follicular B cell fate in the spleen where MZB cell fate 
specification in the spleen depends upon nonredundant interaction between Notch2 and 
Dll1, (Pillai and Cariappa, 2009; Radkte et al., 2009) . Notch signaling has also been 
implicated as a key regulator of peripheral T cell activation and effector cell 
differentiation (Yuan et al., 2010; Radtke et al., 2009).  
Drosophila and mammalian Notch receptors are first synthesized in precursor 
form as 300-350 kD type 1 single-pass transmembrane glycoproteins. During 
maturation, mammalian Notch precursor polypeptides are proteolytically processed by a 
furin-like convertase at a site called S1, yielding two non-covalently associated 
subunits. The resulting two associated subunits, termed extracellular Notch (NEC) and 
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transmembrane Notch (NTM), constitute the mature heterodimeric form of the protein 
present at the cell surface (Kovall and Blacklow, 2010). Notch receptors have a modular 
domain organization. The ectodomains of Notch receptors consist of a series of N-
terminal epidermal growth factor (EGF)-like repeats that are responsible for ligand 
binding. The number of EGF-like repeats varies by species and receptor subtype. O-
linked glycosylation of these EGF repeats, including modification by O-fucose, Fringe, 
and Rumi glycosyltransferases, modulates the activity of Notch receptors in response to 
different ligand subtypes. The EGF repeats are followed by three LIN-12/Notch repeat 
(LNR) modules, which are unique to Notch receptors and participate in preventing 
premature receptor activation.  The heterodimerization (HD) domain of Notch 1 is 
divided by furin cleavage, so that its N-terminal part(HD-N),terminates the NEC 
subunit, and its C-terminal half (HD-C) constitutes the beginning of the NTM subunit. 
Following the extracellular HD-C region, NEC has a transmembrane segment and an 
intracellular region (ICN).  The intracellular region is composed of an RBPJk-
association module (RAM) domain, seven ankyrin (ANK ) repeats flanked by two 
nuclear localisation signals(NLS),a transactivation domain(TAD) and a PEST domain 
that harbours degradation signals necessary for the eventual deactivation of the NICD 
by proteolysis (Schimdt et al., 2010; Kovall and Blacklow, 2010 ).  
Dysregulation of Notch signaling has a been implicated in a wide range of 
human diseases like developmental disorders such as familial aortic valve disease 
caused by mutations within the Notch1 receptor or adult onset diseases such as cerebral 
autosomal dominant rteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), where patients suffer from stroke and dementia due to mutations in the 
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Notch3 receptor (Kopan and Llagan et al., 2009). Furthermore, the deregulation of 
Notch has been implicated in neoplastic diseases such as breast cancer, 
adenocarcinoma, medulloblastoma and glioma (Koch and Radtke, 2010) A truncated, 
constitutively active form of mammalian Notch1, termed TAN-1, due to a (7; 9) 
chromosomal translocation has been implicated in human T-ALL (Ellison et al., 1991) 
where it is seen in more than 50% of all cases (Weng et al., 2004). 
 
1.5 Notch Ligands 
 
Canonical Notch ligands are type I transmembrane proteins belonging to two 
related families, Delta-like (DLL) and Jagged (Delta and Serrate in Drosophila). Both 
families contain highly conserved N-terminal DSL domains and varying numbers of 
EGF repeats in their extracellular domains (Yuan et al., 2010). DLL 3 appears unable to 
activate Notch in vitro or to bind Notch receptors on hematopoietic cells (D’Souza et 
al., 2010) 
Most interestingly, Notch ligands are regulated by intracellular trafficking, as 
DSL ligands accumulate at the cell surface in the absence of endocytosis and do not 
further activate Notch signaling. The intracellular domains of DLL 1, DLL 4, Jagged1 
and Jagged2 contain multiple ubiquitination sites that are targeted by E3 ligases such as 
Neuralised (Neur) and Mind bomb (Mib). However, only Mib1 acts in the ligand-
presenting cell and is therefore essential for the regulation of Notch signaling. 
Expression of Jagged ligands, but not Dll, on the surface of APCs was shown to 
induce Th2 cell differentiation in vitro (Amsen et al., 2004). Furthermore, Benedito et 
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al., showed that Jagged 1 is a potent proangiogenic regulator in mice that antagonizes 
Dll4-Notch signaling in cells expressing Fringe family glycotransferases. Mukherjee et 
al., 2009 showed that in the presence of skewing cytokines, DLL4 influences the 
generation of IL-17-producing T cells. In the absence of Notch signals, IL-17 
production was significantly inhibited even under specific skewing conditions. These 
studies demonstrate that DLL4 up-regulates Rorc expression in T cells. 
DSL family members represent the classical Notch ligands. But expanding 
repertoires of non-canonical ligands have been identified. Unlike the canonical ligands, 
these ligands lack the DSL domain required to interact with Notch and comprise a 
group of structurally diverse proteins that include integral and 
glycosylphosphatidylinositol(GPI)-linked membrane as well as secreted proteins. 
Membrane-tethered non-canonical ligands include Delta-like 1(Dlk-1) which is one of 
the first reported non canonical ligands for Notch and is best known  for its role in 
preventing adipogenesis(D’Souza et al., 2010). Dlk-1 is structurally similar to Delta-
like proteins even though it lacks a DSL domain. It is cleaved by ADAMs and is 
negatively regulated by Notch signaling. 
 
1.6 Canonical Notch signaling 
 
Upon binding Delta-like or Jagged ligands, Notch undergoes two proteolytic 
cleavages. The first cleavage is catalyzed by Adam-family proteases while the second 
cleavage is mediated by the gamma secretase complex (an enzyme complex that 
contains presenilin, nicastrin, PEN2 and APH1) leading to the translocation of the 
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Notch intracellular domain (N-ICD) into the nucleus. Canonically Notch interacts with 
the transcriptional repressor CSL (CBF-1, Suppressor of Hairless, Lag-1). N-ICD 
interaction with CSL displaces transcriptional corepressors from CSL and also recruits 
Mastermind (MAML) protein. The new transcriptional complex of N-ICD-CSL--
MAML converts CSL from a repressor to a transcriptional activator leading to the 
activation of target genes (Osborne et al., 2006; Bray et al., 2006). 
 
1.7 Non-canonical Notch signaling 
 
The term non-canonical Notch signaling was originally used to describe 
signaling events that are Notch dependent but do not rely on CSL (Minter and Osborne, 
in press). In some instances it has become apparent that non-canonical Notch signaling 
may occur in the cytosol giving rise to the name non-canonical, non-nuclear Notch 
signaling (Minter and Osborne, in press). An example of non-canonical, non-nuclear 
Notch signaling is shown in data by Sarin et al., 2009 where they describe a signaling 
cascade activated by Notch, which inhibits apoptosis triggered by neglect in mammalian 
cells. In this pathway, the Notch intracellular domain (NICD), which is released after 
interaction with ligand, converges on the kinase mammalian target of rapamycin 
(mTOR) and the substrate-defining protein rapamycin independent companion of 
mTOR (Rictor), culminating in the activation of the kinase Akt/PKB. Akt regulates 
processes related to proliferation, metabolism, growth, and survival. Data from Sarin et 
al., 2009 identified AktS473 as a key downstream target in the antiapoptotic pathway 
activated by NICD. 
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Data from our lab also points to the existence of non-canonical nuclear Notch 
signaling since Notch has been found to be associated with the NF-β proteins, p50 or 
c-rel (Shin et al., 2006). Recently, ligand-independent Notch signaling has been shown 
to occur in circulating blood cells in drosophila, where in the absence of Notch ligand 
provided by neighbouring cells, Notch signaling is activated through stabilization with 
the transcription factor HIF-1 α (Mukherjee et al., 2011). The study shows that HIF-1 α 
and Notch colocalize in endocytic vesicles, where HIF-1 α stabilizes Notch and allows a 
HIF-1 α-NICD to transcriptionally activate target genes.  
 
1.8 Pharmacological inhibition of Notch signaling 
 
Blocking the Notch pathway can be achieved by using small compounds that 
target the activity of the gamma-secretase-presenilin complex that releases the 
intracellular NICD upon Notch receptor activation. Two commonly used GSIs (gamma-
secretase inhibitors) are ILCHO and Compound E ((s,s)-2-[2-(3,5-difluorophenyl)-
acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-
yl)-propionamide). 
These inhibitors were originally developed to block the proteolysis of the 
amyloid precursor protein (APP) thus preventing the accumulation of Aβ peptide during 
progression of Alzheimer’s disease. Unfortunately, GSIs affect a broad spectrum of 
pathways and are not specific to Notch signaling, thus confounding results and 
producing unintended consequences. Nevertheless, GSIs are approved in for use in 
clinic trials and are currently being used in the treatment of Alzheimer and several types 
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of cancer including, prostate, breast, pancreatic and lung cancer, melanoma and T cell 
acute lymphoblastic leukemia (http://clinicaltrials.gov/2011). 
Notch signaling regulates cell renewal and binary fate decisions in the adult 
intestine. Ablation of Notch signaling in the intestine, using RBPjk conditional 
knockout mice, GSI, dibenzazepine, or double knockout of Notch1/Notch2specifically 
increases the number of goblet cells at the expense of ISCs(intestinal stem cells) and 
absorptive enterocytes (Riccio et al., 2008). Thus, an unfortunate side effect following 
GSI treatment is severe gut toxicity. However, a recent report has shown that 
combination therapy employing GSI and glucocorticoids reduced GSI-associated 
intestinal toxicity and improved its antileukemic effects (Real et al., 2009). 
 
1.9 Experimental Autoimmune Encephalomyelitis (EAE) 
 
EAE was the first identified and is the best characterized animal model of 
human autoimmune disease. This model has had a major role in identifying and 
characterizing aspects of immune surveillance, inflammation and immune-mediated 
tissue injury, (Baxter 2007). It is characterized histologically by the infiltration of 
inflammatory cells, axonal damage and demyelination of nerve fibers in the CNS. The 
symptoms are characterized by an ascending paralysis and neurological signs. It shares 
clinical and pathological features with Multiple Sclerosis (MS) and is used as a model 
for the human disease (Mills et al., 2010).  
A variety of methods are used to induce EAE including the injection of an 
encephalitogenic peptide of a myelin protein, or injection of spinal cord homogenate. 
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Adoptive (or passive transfer) of spleen and lymph node cells from an immunized 
animal into a naiive animal can also induce disease. (Emerson et al., 2009). EAE is 
induced in SJL mice by injecting PLP 139-151 antigen, this model is characterized by 
the relapsing remitting form of EAE. The injection of MOG peptide induces EAE in the 
C57Bl6 mouse model, producing a chronic progressive form of the disease.  
EAE is mediated by myelin-specific T cells, which are activated in the periphery 
and translocate into the CNS following permeabilization of the BBB. Upon entering the 
CNS, the T cells are reactivated by local and infiltrating activated antigen-presenting 
cells (APC), which present major histocompatibility complex (MHC) class II-associated 
peptides, resulting in subsequent inflammatory processes and eventually in 
demyelination and axonal damage (Fletcher et al., 2010). The importance of CNS 
homing in the development of EAE was confirmed by the fact that deficiency in C-C 
type chemokine receptor 6 (CCR6), a chemokine receptor expressed on Th17 cells, 
conferred resistance to EAE, although CCR6
-/-
 mice still developed peripheral Th17 
responses (Reboldi et al., 2009). 
Previously, EAE was thought to be a Th1 mediated disease but now it is 
believed to be mediated by both Th17 and Th1 cells. In fact, a study done by Kebir et 
al., 2009 showed that a subpopulation of Th17 lymphocytes that coexpressed IFN- and 
IL-17 preferentially crossed the human BBB and that this same subpopulation 
accumulated in the CNS of mice during the effector phase of EAE. It seems that Th1 
and Th17 play slightly different roles in EAE since IL-12-polarized T cells promote 
expression of monocyte attracting chemokines and macrophage-rich infiltrates into the 
spinal cord, whereas IL-23-polarized T cells activate neutrophil-attracting chemokines 
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and promoted neutrophils, especially in the brain (Kroenke et al., 2008). A direct 
interaction of Th17 cells with neurons resulting in neuronal dysfunction in both axons 
and neuronal cell bodies been actually demonstrated by Siffrin et al., 2010. Th9 cells 
have also been found to induce EAE (Jager et al., 2009). 
 
1.10 Multiple Sclerosis 
 
MS is a chronic, progressive inflammatory disorder of the brain and spinal cord. 
The inflammatory plaque, whether determined histopathologically or by using magnetic 
resonance imaging (MRI), is the pathological hallmark of MS. Like EAE, it is thought 
that the disease is mediated by pathogenic T cell responses against myelin antigens, 
followed by a broader neurodegenerative process. The key morphological feature of MS 
is primary demyelination of nerve axons leading to signal conduction block or 
conduction slowing at the site of demyelination. Neurological symptoms develop when 
conduction block occurs simultaneously in a significant proportion of fibers within a 
given pathway (Fletcher et al., 2010). Patients usually present in early adulthood with a 
relapsing/ remitting form of the disease that over time develops into a chronic 
progressive state with increasing disability (Brosnan et al., 2009). 
Currently available therapies for MS are aimed primarily at reducing the number 
of relapses and slowing the progression of disability.  Options include beta-interferons, 
glatiramer acetate, mitoxantrone, and natalizumab. IFN-β drugs likely have multiple 
effects on the immune system. The effects in the periphery include inhibition of antigen 
presentation, and at the blood-brain barrier there is down-regulation of adhesion 
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molecules and decreased production of matrix metalloproteinases. This limits the entry 
of T cells into CNS (Derwenskus et al., 2011). Glatiramer Acetate (GA) (Copaxone 
Teva Pharmaceutical Industries Ltd) is a random mixture of polypeptides containing 
alanine, glutamic acid, lysine and tyrosine. GA was found to suppress MBP-induced 
EAE (Teitelbaum et al., 2004). Its mode of action is unclear but it has been shown to 
compete with MHC binding of MBP and limit activation of MBP reactive T-cells. GA 
also leads to a shift in the T-cell population toward a Th2 cytokine response profile 
(Kim et al., 2004). It has been proposed that these Th2 cells migrate through the BBB 
into the brain parenchyma, where they are activated. As a result, they produce 
immunomodulatory cytokines that counteract the proinflammatory Th1 response, an 
effect called "bystander suppression." GA reactive T-cells have also been shown to 
secrete brain-derived neurotrophic factor (BDNF), which has anti-inflammatory and 
neuroprotective functions (Ziemssen et al., 2002).  
Natalizumab (Tysabri[R], Biogen-Idec/Elan) is a humanized monoclonal 
antibody (mAb) that targets alpha4beta1-integrin, acting as a selective adhesion 
molecule inhibitor. The glycoprotein alpha4beta1 integrin is also known as very late 
antigen 4 (VLA4). It is expressed on the surface of lymphocytes and monocytes and 
plays an important role in cell adhesion and trafficking across the blood-brain and other 
endothelial barriers. It is not clear exactly how natalizumab exerts its clinical effect but 
is thought to be due to the significantly reduced migration of leukocytes into the CNS 
parenchyma ( Farrell and Giovannoni, 2010). Mitoxantrone (Novantrone[R] Serono) 
was originally designed as a chemotherapeutic agent and is most commonly used in 
treating breast cancer. It is an anthracenedione that inhibits topoisomerase-2, preventing 
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the successful unwinding of DNA. It is currently licensed for use in patients with 
aggressive relapsing MS who have failed first-line therapy. Mitoxantrone has an 
immunosuppressive action, inhibiting the proliferation of T-cells, B-cells, and 
monocytes and reducing secretion of proinflammatory cytokines (Farrell and 
Giovannon, 2010). 
 
1.11 Notch and Multiple Sclerosis  
 
MS is an inflammatory, demyelinating disease of the CNS that is thought to be 
mediated by an immune attack directed against oligodendrocytes and myelin. 
Activation of the Notch pathway has been shown to inhibit oligodendrocyte precursor 
cells (OPC) differentiation and to hamper their ability to remyelinate damaged fibers. 
Blocking the Notch pathway activation in oligodendrocytes promotes remyelination, 
reduces axonal damage and significantly enhances clinical recovery from the disease 
(Selmaj et al., 2008).  In addition, the IL-17/IL-23 axis is clearly an important drug 
target for the treatment of MS (Mills et al., 2008), and hence any protein that regulates 
IL-17 becomes of therapeutic interest. 
 
1.12 Rationale 
 
Th1 cells were originally thought to be the main pathogenic T cells in EAE and 
MS. This conclusion was based partly on the observation that IL-12p40-defective (IL-
12p40
-/-
) mice were resistant to EAE (Langrish et al., 2005; Matusevicus et al., 1999). 
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Since IL-12 is required for differentiation of Th1 cells, it was concluded that Th1 cells 
were the essential pathogenic cells. Similarly, adoptive transfer of Th1 cells caused the 
induction of disease in mice and treatment of MS patients with IFN-γ exacerbated 
disease. 
However, vast amounts of confusing data emerged. IFN-γ-/- or STAT1-/- mice 
lacking Th1 cells were found to develop more severe EAE. In addition, Langrish et al., 
2005 demonstrated that PLP-specific T cells cultured in the presence of IL-23 generated 
Th17 cell lines induced EAE following passive transfer into naive SJL mice, whereas 
Th1 cells lines generated by in vitro culture with IL-12 failed to induce EAE. 
Furthermore administration of neutralizing anti-IL-17 antibody reduced the severity of 
EAE, while blocking IFN-γ exacerbated disease. 
These conflicting data were resolved partly following the discovery of IL-23, 
which is related structurally to IL-12. IL-23 shares the p40 chain with IL-12, which is 
associated with either a separate p19 or p35 chain for IL-23 and IL-12, respectively. IL-
23p19
-/-,
 like the IL-12p40
-/-
, mice were found to be resistant to EAE, whereas IL-
12p35
-/-
 mice were susceptible. Since the IL-23 cytokine is essential for the 
maintenance and expansion of the Th17 lineage. (Fletcher et al., 2010), it was 
concluded that Th17 cells played a major role in the pathogenesis of MS and EAE. 
Previous work in our lab (Minter et al.,  2005) showed that inhibiting Notch 
signaling relieved symptoms of EAE through the inhibition of the transcription factor T-
bet and consequently through the inhibition of IFN. With the advent of the new 
information concerning Th17 cells, the possibility arose that inhibiting Notch signaling 
had a negative effect on Th17 cells. My thesis was designed to ask whether Th17 cells 
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also required Notch signaling and whether blockade of Notch has any effect on Th17 
mediated disease. 
1.13 AIMS 
The aims of my research were as follows: 
Aim 1: Does Notch play a role in the development / differentiation of Th17 cells in 
vitro? 
1.1 Does Notch signaling regulate Th17 cell differentiation in vitro? 
1.2. What is the mechanism by which down regulation of Th17 cytokines occurs? 
1.3. To genetically validate results seen by the use of Conditional Notch1 knockout mice 
1.4 Does Notch signaling regulate Th17 cell differentiation in knockout mice? 
Aim 2: Does Notch play a role in the differentiation of Th17 cells in vivo? 
2.1. Does Notch inhibition prevent the development of EAE? 
2.2. Does Notch inhibition prevent the differentiation of PLP-specific Th17 cells? 
2.3. Use of Conditional Notch1 knockout mice in EAE experiments 
Aim 3: Does Notch 3 play a role in differentiation of Th17 cells in vitro? 
3.1. Does Notch 3 signaling regulate Th17 cell differentiation in vitro? 
Aim 4: To investigate the role of non-canonical Notch signaling in Th17 development 
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FIGURE 1: CD4
+
 T helper lineages.
Each lineage is induced by specific cytokines that induce specific transcription factors 
that result in a certain cytokine profile. 
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(Trojantec) 
Figure 2: Notch Receptors. 
 The extracellular portions of all four mammalian Notch receptors contain epidermal 
growth-factor-like repeats, which bind to ligands. These are followed by three LIN 
repeats. The intracellular portion contains a RAM domain (RBP-J-associated molecule) 
that binds CSL and 7 Ankyrin repeats that are used for protein binding. At either end of 
the Ankyrin repeats are nuclear localization signals. The transcriptional activation 
domain (TAD) activates downstream targets. Notch 3 and 4 do not have a TAD domain. 
The PEST domain regulates the degradation of Notch proteins. 
25 
Figure 3: Canonical Notch signaling 
After engagement with one of its ligands, Notch undergoes cleavage events mediated through ADAM proteases 
and gamma-secretase, as designated by the lighting symbol. Notch then translocates to the nucleus where it binds 
to CSL to activate downstream targets. 
Courtesy of J.Samon 
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Figure 4: Summary of possible canonical and non-canonical roles for Notch 
signaling in T cells. 
 A: Canonical Notch signaling; NICD –CSL complex binds to DNA. B: Non-canonical 
nuclear Notch signaling; NICD is associated with NFB units. C: Non-canonical 
nonuclear Notch signaling; NICD is associated with AKT. 
C B A 
Modified from Osborne and Minter 2012, in press 
27 
Figure 5: Migration and effector function of T cells in the CNS during EAE. 
After immunization with myelin antigens, DCs are activated in the lymph nodes and 
present myelin antigen to naive T cells. The activated myelin-specific T cells enter the 
bloodstream and traffic to and enter the CNS. Breakdown of the BBB occurs, allowing 
recruitment of other inflammatory cells into the CNS. T cells expand and release 
inflammatory mediators which help recruit other immune cells to the site of 
inflammation. Activation of local microglial cells and infiltrating cells results in 
production of cytotoxic agents which promote myelin breakdown. Damage to the myelin 
sheath surrounding axons is followed by axonal damage and neurological impairment. 
(Fletcher et al., 2010) 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Mice 
C57B6 mice for in-vitro experiments were obtained from Jackson laboratories. 
SJL/J mice used in EAE experiments were purchased from Charles River Laboratory 
(Wilmington, MA).Notch1 conditional knock-out mice were obtained from our 
collaborators in Umass, Amherst. They obtained Notch1 conditional floxed mice by 
crossing Notch1fl/fl (Notch1tm2Rko/GridJ) to MxCre+/- (B6.Cg-Tg (Mx1-cre) 1Cgn/J) 
from Jackson Laboratory (Bar Harbor, ME.). Homozygous Notch-1 fl/fl females were 
mated to Notch1fl/fl x MxCre+/- male mice to maintain breeding pairs. 
CSL knock-out mice were similarly obtained by crossing homozygous female 
CSL 
fl/fl
 (kindly provided by V.Shapiro, Mayo Clinic) with MxCre
+/- 
males. Notch3 
knock-out spleens were kindly provided Spyros Artavanis-Tsakonas, Harvard 
University. All mice were housed in the Animal Care Facility at the University in 
accordance with the Institutional Animal Care and Use Committee guidelines 
2.2 In Vivo Floxing of Notch-1 and CSL mice 
Notch1 
fl/fl
 x MxCre
+/-
 mice, Notch1 
fl/fl
 x MxCre
-/- 
mice, CSL fl/fl x MxCre+/- and 
CSL 
fl/fl
 x MxCre
-/-
 mice were given 5 IP injections of Poly(I)-Poly(C), Amersham 
Biosciences (Piscataway, NJ), at a dose of 12-15 μg per gram of weight every other day. 
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Notch1 and CSL 
fl/fl
 x MxCre
+/- 
control mice were given equal amounts of PBS vehicle. 
Mice were then rested for 3 weeks after the last injection before being used in 
experiments. 
 
2.3 Antibodies 
Anti-Notch 3(AF1308) and anti-Notch 1 (AF5267) antibody were obtained from 
R&D systems. For detection of mouse activated Notch1, anti-Notch 1 (ebioscience, 
mN1A clone) was used. β-actin antibody (Sigma Aldrich, St Louis) was used as a 
loading control. 
 
2.4 Drugs and chemicals:  
γ-secretase inhibitors Compound E (Alexis Biochemicals, San Diego, CA), and 
ILCHO (Palaga et al., 2003) were resuspended in DMSO and used in concentrations as 
indicated in figure legends. 
 
2.5 Cell culture and in-vitro polarization 
 For in-vitro polarization assays CD4 T cells were cultured and polarized 
according to Keervisthan et al., 2011.Briefly cells (2.5- 3 106/ml) were pretreated in 
vitro at 37°C for 30 min with 10mg/ml anti-Notch3 or with anti-Notch1 antibody, 0.1% 
DMSO,GSI (25 μM ILCHO or 4 μM Compound E) or JLK6 inhibitor (7-Amino-4-
chloro-3-methoxy-1H-2-benzopyran) (Tocris Bioscience) and then plated onto 12- or 6-
well plates precoated with 1 mg/ml each anti-CD3 and anti-CD28. To polarize CD4
+ 
T 
cells to a Th17 phenotype, 20 ng IL-6 (R&D Systems, Minneapolis,MN), 5 ng TGF-b 
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(R&D Systems), and 10 mg both anti–IFN-g (BD Pharmingen) and anti–IL-4 (BD 
Pharmingen) were used per milliliter of cells. Cells were polarized for 24, 48, or 72 h. 
The activation supernatants were evaluated for IL-17A (BD Biosciences). 
 
2.6 Intracellular and cell surface staining 
Mouse CD4
+
 T cells were polarized toward a Th17 phenotype as described 
above. After 72 h, the cells were stimulated by adding 80 nM PMA and 2.5mM 
ionomycin  in addition to brefeldin A for 5 h. Cells were fixed and permeabilized using 
the BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s 
instructions. Fluorescent Abs (anti-mouse CD4-FITC, anti-mouse IL-17A-
allophycocyanin, and anti-mouse IFN--PE) were obtained from BD Biosciences. Anti-
mouse Notch1-PE was obtained from eBioscience. Cells were analyzed on a FACS 
LSR II (Becton Dickinson).  
 
2.7 Real time PCR 
 CD4
+
 T cells cultured as above were harvested and total RNA was isolated 
using the RNAqueous kit (Ambion, Austin, TX). Total RNA samples were subjected to 
treatment with DNase using the TURBO DNA-free kit (Ambion), cDNA was 
synthesized, and transcripts were amplified by quantitative real time polymerase (Q-
PCR Stratagene MX3000P). Primer sequences for IL-17 were: (Forward): 5’-CTC CAG 
AAG GCC CTC AGA CTA C-3’, (Reverse): 5’-AGC TTT CCC TCC GCA TTG ACA 
CAG-3’ (1).  RORγt (Forward): 5′-TTT GGA ACT GGC TTT CCA TC-3′, (Reverse): 
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5′-AAG ATC TGC AGC TTT TCC ACA-3′. The expression of each gene was 
normalized to the expression of β-actin by the 2-∆∆CT method (2). 
 
2.8 In-vivo GSI treatment 
For the EAE experiments, 8-12 weeks old female SJL/J mice were purchased 
from Charles River Laboratory (Wilmington, MA).  All mice were housed in the animal 
care facility at the University of Massachusetts, Amherst in accordance with the 
Institutional Animal Care and Use Committee (IACUC) guidelines. The GSI 
administered in-vivo was LY-411,575 (LY) formulated for two doses 5mg/kg and 2.5 
mg/ kg. Mice were fed 5mg/kg LY chow for four weeks. . They were then fed 2.5mg/kg 
LY chow for a week,immunized at that point, and after a total of two weeks on the 
2.5mg/kg LYchow, they were  returned to the 5mg/kg LY chow until the end of the 
experiment.  
 
2.9 EAE Induction and Evaluation 
EAE was induced by immunizing mice in the flank with 50μg PLP 
(139-151)
 
(Invitrogen, Carlsbad, CA) supplemented with 400μg Mycobacterium tuberculosis 
H37RA (Difco, Detroit, MI). Pertussis toxin (Ptx; Sigma 200ng) was injected 
interaperitonially on the day of immunization. The progression and severity of disease 
was monitored and scored from 0-5 as follows: Score 0-no disease; 1-limp tail, 2-hind 
limb weakness; 3-hind limb paralysis; 4-hind and fore limb paralysis; 5-morbidity and 
death. Data is reported as the mean daily clinical score (3-5). 
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Mice were anesthetized and perfused through the left cardiac ventricle with PBS 
during the peak of disease (day 15 post immunization). Spinal cords and spleens were 
removed by dissection.  Splenocytes were cultured at 37°C with medium alone or with 
different concentrations of PLP (139-151) antigen for 5 days. To prepare a single cell 
suspension, spinal cords were cut into pieces and the tissues were mashed and passed 
through a 70 μm mesh. Mononuclear cells were isolated over a Percoll gradient and 
were then cultured with PLP (139-151) antigen for 5 days. Cells from the spinal cord were 
stained for CD4
+
 and CD8
+
 T cells. IL-17 and IFNγ ELISAs were then performed on 
supernatants from all re-stimulated cells. Splenocytes were intracellularly stained for 
IL-17. 
 
2.10 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 4.0. Unpaired 
t-test (α =0.05) were used when comparing two conditions. 
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3.1 Introduction  
The regulation of Th17 differentiation from naïve CD4
+
 T cells is an area of active 
investigation. Th17 cells and the pro-inflammatory cytokines (IL-17A, IL-17F, IL-21 
and IL-22) produced by these cells, have been implicated in several autoimmune and 
inflammatory disorders (Bettelli et al., 2007; Weaver et al., 2007). The importance of 
this subset in autoimmune diseases was first recognized when mice lacking expression 
of the p19 subunit of IL-23, a cytokine involved in differentiation and expansion of 
Th17 cells, failed to develop certain autoimmune disorders (Cua et al.,2003;Langrish et 
al., 2005) . The pathogenic role of IL-17 as well as Th17 cells has now been 
documented in numerous autoimmune diseases including multiple sclerosis 
(Matusevicius e et al., 1999), rheumatoid arthritis (Chabaud et al., 1999), psoriasis 
(Kagami et al., 2009), Crohn’s disease (Sakuraba et al., 2009) and systemic lupus 
erythematosus (Nalbandian et al., 2009).  
Several factors are known to affect Th17 differentiation including antigenic stimuli 
(Mukherjee et al., 2009), expression of particular transcription factors (Zho et al., 2009) 
and epigenetic changes in the IL-17 gene locus (Akimzhanov et al., 2007). The cytokine 
milieu leading to Th17 differentiation is the most carefully studied factor.  In mice, it is 
known that IL-6 along with proinflammatory cytokines TGF-β and IL-21, promotes 
differentiation of naïve CD4
+
 T cells into the Th17 lineage (Ivanov et al., 2007). (6). 
Manel et al., 2008 have similarly shown that human Th17 differentiation requires 
exposure to low doses of TGFβ in concert with IL-1β, IL-6, IL-21 and/or IL-23. In 
addition to the cytokine environment, transcription factors are important determinants 
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of Th17 differentiation (Ivanov et al., 2007; Egwuagu et al., 2009); Ziegler et al., 2009. 
The transcription factor retinoic acid receptor related orphan receptor γt (RORγt), in co-
operation with RORα controls Th17 differentiation (Yang et al., 2008). Th17 
differentiation also is regulated by histone-3 acetylation and H3Lys-4 methylation in 
both the IL-17A and the IL-17F promoters in a lineage dependent manner (Akimzhanov 
et al., 2007). Despite great progress in understanding the molecular mechanism of Th17 
differentiation, the contribution of cell surface proteins found on CD4
+ 
T cells is not 
well understood.  
Notch proteins, are type 1 transmembrane proteins known to play a crucial role in cell 
fate determination in many cell lineages including early T cell development in the 
thymus (Deftos et al., 2000). Four Notch receptors (Notch1, 2, 3 and 4) are found in 
mammals.  In developing T cells, Notch1 has been reported to regulate αβ versus γδ T 
cell differentiation (Garbe et al., 2007). T versus B cell fate determination (Radtke et 
al., 2004) and CD4
+
 versus CD8
+
 T lineage decision (Germain et al., 2002). Notch1 is 
also present on naïve (Amsen et al., 2004) and activated CD4
+
 T cells (Adler et al., 
2003). Additionally, we and others have shown that Notch1 signaling is activated upon 
crosslinking of the T cell receptor (TCR) (Adler et al., 2003; Palaga et al., 2003). 
Canonical Notch signaling is induced when one of the four mammalian Notch receptors 
(Notch1, 2, 3 or 4) encounter one of the five known ligands (Jagged 1, 2 or 3 or Delta 
like-1 or 2) on a neighboring cell.  This interaction initiates a proteolytic cleavage of the 
transmembrane Notch peptide near the extracellular surface by an ADAM protease, 
which, in turn, induces a conformational change that allows access and cleavage of the 
Notch transmembrane domain by the - secretase complex.  Cleavage of Notch 
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receptors by -secretase results in the release of an intracellular Notch domain (NICD), 
which rapidly translocates to the nucleus where it interacts with the DNA binding 
protein known as CSL (CBF-1, Suppressor of Hairless, Lag-1).  In the absence of Notch 
signaling, CSL is bound to DNA in a complex with several repressor proteins.  NICD 
translocation to the nucleus and binding to CSL results in disruption of the repressor 
complex followed by recruitment of several co-activator proteins resulting in the 
initiation of transcription of genes located downstream of Notch/CSL complexes 
(Osborne et al., 2006; Miele et al., 2006).  
Notch is reported to play a critical role in Th1 (Minter et al., 2005);Maekawa et al., 
2003) and/or Th2 (Fang et al., 2007; Amsen et al., 2007) mediated immune responses. 
Data from several laboratories suggest that antigen presenting cells (APCs) expressing 
Delta like-4 (DLL-4) drive the differentiation of Th1 cells (Skokos et al., 2007; Kassner 
et al., 2010) while APCs expressing Jagged1 promote differentiation of Th2 cells 
(Amsen et al., 2004; Liotta et al., 2008).  
In this study, we examined the role of Notch signaling in Th17 polarization. We used 
pharmacologic inhibitors as well as knockdown approaches to establish a role for Notch 
signaling in Th17 polarization. Promoter analysis and chromatin immunoprecipitation 
assays demonstrated regulation of both the IL-17 and RORγt promoters by Notch1. 
Lastly, we present in-vivo data demonstrating that inhibition of Notch signaling 
ameliorates the severity of EAE, a murine autoimmune disease that displays several 
characteristics of human multiple sclerosis.  These data provide further understanding of 
the Th17 differentiation pathway and suggest opportunities for exploiting the Notch 
signaling pathway to treat Th17 mediated autoimmune disorders. 
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3.2 Materials and Methods  
 3.2.1. Drugs and chemicals 
γ-secretase inhibitors Compound E (Alexis Biochemicals, San Diego, CA), and 
ILCHO(Palaga et al., 2003) were resuspended in DMSO and used in concentrations as 
indicated in figure legends.  
 3.2.2 Antibodies 
For detection of human Notch 1, anti-Notch1 (C20) (Santa Cruz) and anti- activated 
Notch 1 (Rockland, Gilbertsville, PA) antibodies were used. Anti-Notch2 (Abcam, 
Cambridge MA), anti-Notch3 (M134) (Santa Cruz, CA) and anti-Notch4 (H225) (Santa 
Cruz, CA) were also used. For detection of mouse activated Notch1, anti-Notch 1 
(ebioscience, mN1A clone) was used.  β-actin antibody (Sigma Aldrich, St Louis) was 
used as a loading control. 
 3.2.3 Cell culture and mouse in-vitro polarization 
For mouse in-vitro polarization assays, naïve CD4
+
 T cells were isolated from C57BL/6 
(Jackson Laboratories) using the IMag magnetic system (BD Pharmingen, San Jose, 
CA), according to the manufacturer’s protocol. Cells (2.5 x106/ml) were pretreated in-
vitro at 37
0
C for 30 min with 0.1% DMSO or with GSI (25 μM ILCHO or 4 μM 
Compound E) and then were plated onto 12 or 6 well plates precoated with 1µg/ml each 
of αCD3 and αCD28. To polarize CD4+ T cells to a Th17 phenotype 20 ng of IL-6 
(R&D Systems), 5 ng of TGF-β (R&D Systems) and 10 μg of both anti IFNγ (BD 
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Pharmingen) and anti-IL-4 (BD Pharmingen) were used per ml of cells (Betteli et al., 
2006; Quintant et al., 2008). Cells were polarized for 24, 48 or 72 h. The activation 
supernatants were evaluated for IL-17A (BD Biosciences), IL-17F (R&D) and IL-21 
(R&D) by ELISA. To study the effect of Notch inhibition on fully differentiated Th17 
cells, naïve CD4
+
 T cells were differentiated towards the Th17 lineage for 4 days. These 
cells were then treated with either DMSO or ILCHO followed by culturing in α-CD3 
coated plates. After 24 hours, supernatants were collected and analyzed for IL-17 
cytokine by ELISA (BD Biosciences). 
3.2.4 Cell culture and human in-vitro polarization 
Human in-vitro Th17 polarization was performed using a modified protocol from Manel 
et al., 2008. Naïve CD4
+
 T cells were purified from peripheral blood mononuclear cells 
by negative selection using MACS separation according to the manufacturer’s 
instructions (Miltenyi Biotech, Sunnyvale, CA) and were cultured in a 37
0
C at 5% CO2 
in serum free X-VIVO 10 media (BioWhittaker, Maryland). Naïve cells (2 x 10
6 
per ml) 
were plated in 24 well plates with beads coated with αCD3 and αCD28 (Dynabeads, 
Invitrogen, Norway) at a concentration of 1 bead per cell.  Antibodies and cytokines 
were added at the time of plating at the following concentrations: 10 U/ml IL-2, 5 ng/ml 
TGF-β1, 10 ng/ml IL-6, 10 ng/ml IL-23, 10 ng/ml IL-21, 10 ng/ml IL-1β, anti-IL-4 
(10μg/ml) and anti IFNγ (10μg/ml). All antibodies and recombinant cytokines used in 
polarization were purchased from R&D systems, MN. IL-17A, IL-17F, IL-21 and IL-22 
protein levels in the activation supernatants were quantified by ELISA (eBioscience, 
San Diego, CA). To evaluate the effect of Notch inhibition on differentiated Th17 cells, 
naïve CD4
+
 T cells were cultured in Th17 polarizing conditions for 4 days followed by 
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treatment with either DMSO or ILCHO. Supernatants were collected after 24 hours and 
analyzed for IL-17 and IL-22 cytokines (eBioscience, San Diego, CA) 
3.2.5 Cell lines and constructs 
HEK 293T cells were obtained from the American Type Culture Collection (Manassas, 
VA) and cultured in DMEM medium (Mediatech, Inc, Manassas, VA) supplemented 
with 10% FBS (Cellgro, Mediatech, Manassa, VA), 2 mM glutamine, and 1 mM 
pyruvate. (Supplements are from Lonza, Walkersville, MD). The Notch1
IC
 encoding
plasmid construct was generated by cloning Notch 1
IC
 cDNA into BamH1 and EcoRI
sites of pcDNA3.0 (Hao et al., 2010). 
3.2.6 Retroviral expression vector and transduction 
The sequence encoding N1
IC
 was subcloned into the retroviral vector LZRS and viral
particles were produced as described previously (Curry et al., 2006). For transduction of 
virus, naïve human CD4
+ T cells were isolated and stimulated with αCD3/αCD28-
coated beads for 24h and transduced with retroviral supernatant in the presence of 8μg 
polybrene as described before (Curry et al., 2006). Transduced cells were then 
differentiated to Th0 or Th17 conditions. The cells were transduced again the following 
day with retroviral supernatants and cultured for an additional 48h. 
3.2.7 Dual Luciferase assay 
HEK 293 T cells were plated on 60 mm dishes and co-transfected with Notch1
IC
 (1μg)
expression vector constructs cloned into pcDNA 3.0  along with a human IL-17 (-
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1125bp) promoter luciferase construct (1μg) kindly provided by Dr Sarah Gaffen 
(University of Pittsburg) (Liu et al., 2004) and 0.1 μg Renilla luciferase construct as the 
internal transfection control. Luciferase assays (Dual Luciferase assay system, Promega, 
Madison, WI) were performed according to the manufacturer’s instructions. 
3.2.8 Intracellular staining and cell surface staining 
Mouse CD4
+
 T cells were polarized towards a Th17 phenotype as described above.
After 72 hours, the cells were stimulated by adding 80 nM PMA (phorbol myristate 
acetate) and 2.5 μM ionomycin for 1h in addition to Brefeldin A for 5 hours. Cells were 
fixed and permeabilized using the BD Cytofix/Cytoperm kit (BD Biosciences) 
according to the manufacturer’s instructions. Fluorescent antibodies (anti mouse CD4-
FITC, anti-mouse IL-17A-APC and anti-mouse IFNγ-PE) were obtained from BD 
Biosciences. Anti-mouse Notch 1-PE was obtained from e-Bioscience.  Cells were 
analyzed on a FACS LSR II (BD Biosciences). 
3.2.9 Real time PCR 
Human naïve CD4
+ 
T cells were polarized to Th17 as described above. RNA was
extracted using the RNeasy mini kit (Qiagen, Valencia, CA). The RNA was then 
DNAase I-treated (Qiagen, Valencia, CA) and cDNA was synthesized using Superscript 
III (Invitrogen, Carlsbad, CA). Quantitative real time PCR was then performed using 
18S rRNA to normalize following the 2
-∆∆CT
 method (2). The primer sequences used
were: Notch1 (Forward): GTC AAC GCC GTA GAT GAC C, (Reverse): TTG TTA 
GCC CCG TTC TTC AG; RORγt (7) (Forward): TTT TCC GAG GAT GAG ATT GC, 
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(Reverse): CTT TCC ACA TGC TGG CTA CA; 18SrRNA (Forward): GGC GCC CCC 
TCG ATG CTC TTA G, (Reverse): GCT CGG GCC TGC TTT GAA CAC TCT.  
Mouse CD4
+
 T cells cultured as above were harvested and total RNA was isolated using 
the RNAqueous kit (Ambion, Austin, TX). Total RNA samples were subjected to 
treatment with DNase using the TURBO DNA-free kit (Ambion), cDNA was 
synthesized, and transcripts were amplified by quantitative real time polymerase (Q-
PCR Stratagene MX3000P). Primer sequences for IL-17 were: (Forward): 5’-CTC CAG 
AAG GCC CTC AGA CTA C-3’, (Reverse): 5’-AGC TTT CCC TCC GCA TTG ACA 
CAG-3’ (1).  RORγt (Forward): 5′-TTT GGA ACT GGC TTT CCA TC-3′, (Reverse): 
5′-AAG ATC TGC AGC TTT TCC ACA-3′. The expression of each gene was 
normalized to the expression of β-actin by the 2-∆∆CT method (Livak et al., 2009). 
3.2.10 RNA- interference  
To knock down the expression of Notch 1, CD4
+
 T cells were purified and 
nucleoporated with siRNA specific for Notch1 or scrambled siRNA (Santa Cruz 
Biotechnology, Santa Cruz, CA), using an Amaxa Nucleoporator system. Briefly, 5-10 
x 10
6
 CD4
+ T cells were resuspended in 100 μl of nucleofector solution and transfected 
with 100 nM siRNA using the U-014 Amaxa nucleofector program (Lonza, 
Switzerland). After transfection, the cells were incubated for 6h at 37
0
C, and stimulated 
with αCD3/CD28 coated magnetic beads under Th17 polarizing conditions for 48 h.  
3.2.11 MTS assay 
Cytotoxicity assay was performed using CellTiter 96 AQueous one solution reagent 
(Promega) as per the manufacturer’s instructions.  
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3.2.12 Chromatin immunoprecipitation assay (ChIP) 
ChIP assays (Upstate Cell Signaling Solutions) were performed using 1x10
7
 naïve CD4
+
 
T cells stimulated with αCD3/CD28-coated magnetic beads (1 bead/cell) under Th0 (no 
cytokines) or Th17 conditions and pretreated with DMSO or GSI (ILCH0) for 24 h. The 
following primers were used for quantitative as well as standard PCR. IL-17 primer sets 
were: 17 CSL1 (Forward): 5’-TTG ACC CAT AGC ATA GCA GC-3’, (Reverse):5’-
TTC AGG GGT GAC ACC ATT TT-3’; 17CSL2 (Forward): 5’-GAA AAT CTC GTG 
TCT CTT GAA CC-3’, (Reverse): 5’-TTC CTC ACA GAT TCC TTG GC-3 ’; 17CSL3 
(Forward): 5’-TTC CAC TTT CCA CTT CCC AC-3’, (Reverse): 5’-TTC CTC CCT 
GTC CTG CTC TA-3’; 17CSL4 (Forward): 5’-CAA TTG GGA AAA GCA AGC AT-
3’, (Reverse): 5’-CCC TAC TGC CCC TCC TCT AC-3’. RORγt primer sets were: 
RCBF1 (Forward): 5’-ATC TCC AGC CTC AGC TTT GA-3’, (Reverse): 5’-GAT 
GCC CCT GTT TTC TTG AG-3’; RCBF2 (Forward): 5’-AGA GGG ACT CCT TGC 
CTC TC-3’, (Reverse): 5’-TCA AAG CTG AGG CTG GAG AT-3’. Antibodies used 
were rabbit anti Notch1 or normal rabbit IgG (Santa Cruz Biotechnology). Conditions 
for real-time PCR were 50
0
C 2min, 95
0
C 10min, 95
0
C 15sec, 60
0
C 1min (40 cycles); 
conditions for semiquantitative PCR were 95
0
C 5 min, 95
0
C 30s, 55
0
C 1min, 72
0
C 30s 
(35 cycles), 72
0
C for 2min. 
3.2.13 In-vivo GSI treatment 
For the EAE experiments, 8-12 weeks old female SJL/J mice were purchased from 
Charles River Laboratory (Wilmington, MA).  All mice were housed in the animal care 
facility at the University of Massachusetts, Amherst in accordance with the Institutional 
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Animal Care and Use Committee (IACUC) guidelines. The GSI administered in-vivo 
was LY-411,575 (LY) formulated for two doses 5mg/kg and 2.5 mg/ kg. Mice were fed 
5mg/kg LY chow for four weeks. . They were then fed 2.5mg/kg LY chow for a week, 
immunized at that point, and after a total of two weeks on the 2.5mg/kg LYchow, they 
were returned to the 5mg/kg LY chow until the end of the experiment.  
3.2.14 EAE Evaluation 
EAE was induced by immunizing mice in the flank with 50μg PLP 
(139-151)
 (Invitrogen, 
Carlsbad, CA) supplemented with 400μg Mycobacterium tuberculosis H37RA (Difco, 
Detroit, MI). Pertussis toxin (Ptx; Sigma 200ng) was injected interaperitonially on the 
day of immunization. The progression and severity of disease was monitored and scored 
from 0-5 as follows: Score 0-no disease; 1-limp tail, 2-hind limb weakness; 3-hind limb 
paralysis; 4-hind and fore limb paralysis; 5-morbidity and death. Data is reported as the 
mean daily clinical score (Serada et al., 2008; Hostetter et al., 2007; Jurynczyk et al., 
2008).  
Mice were anesthetized and perfused through the left cardiac ventricle with PBS during 
the peak of disease (day 15 post immunization). Spinal cords and spleens were removed 
by dissection.  Splenocytes were cultured at 37°C with medium alone or with different 
concentrations of PLP (139-151) antigen for 5 days. To prepare a single cell suspension, 
spinal cords were cut into pieces and the tissues were mashed and passed through a 70 
μm mesh. Mononuclear cells were isolated over a Percoll gradient and were then 
cultured with PLP (139-151) antigen for 5 days. Cells from the spinal cord were stained for 
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CD4
+
 and CD8
+
 T cells. IL-17 and IFNγ ELISAs were then performed on supernatants 
from all re-stimulated cells. Splenocytes were intracellularly stained for IL-17. 
3.2.15 Statistical analysis: 
Statistical analyses were performed using GraphPad Prism version 4.0. Unpaired t-test 
(α =0.05) were used when comparing two conditions. 
 
3.3 Results 
3.3.1 Gamma secretase inhibition (GSI) during murine Th17 polarization results in 
reduced Th17 associated cytokines production 
The effect of GSI on murine production of IL-17A, IL-17F and IL-21 was tested by 
treating Th17 polarized cells with ILCHO and Compound E, two chemically distinct 
GSI that block γ-secretase by different mechanisms. ILCHO is a competitive peptide 
aldehyde inhibitor of γ-secretase activity that is thought to modify the active sites, while 
compound E is a non-peptide, non-transition state, non-competitive inhibitor of γ-
secretase. Naive CD4
+
 T cells were isolated from spleens of 8-12 weeks old C57/BL6 
mice, pre-treated with GSI or DMSO control for 30 min at 37
0
C and cultured in Th17 
polarizing conditions for 24, 48 or 72 hours and IL-17A, IL-17F and IL-21 cytokine 
levels were assessed. The level of IL-17A produced by Th17 cells treated with GSI was 
significantly reduced in comparison to DMSO treated Th17 polarized cells (Figure6A). 
Similarly, a reduction in IL-17F and IL-21 cytokine levels were observed after GSI 
treatment as compared to DMSO (Figure6A). The observed cytokine profiles 
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demonstrate that GSI reduced Th17 associated cytokines from in-vitro differentiated 
Th17 cells. Interestingly we also observed that Notch1 is upregulated in Th17 polarized 
cells as compared to Th0 conditions (Figure6B). 
Notch is a primary target of GSI in CD4
+
 T cells and to ensure that GSI was effective at
reducing Notch1 activation, intracellular levels of Notch1 were assessed by immunoblot 
(Figure 6B) and intracellular staining (Figure6C). These data revealed that Notch1 
protein expression was reduced in Th17 polarized murine CD4
+ 
T cells treated with
GSI. 
To determine the effect of GSI on IL-17A production on a per cell basis, intracellular 
staining of IL-17A was also performed in Th17 differentiated cells pre-treated with 
either DMSO or GSI (ILCHO). We observed a reduction in intracellular IL-17 levels in 
GSI treated Th17 cells as compared to DMSO (Figure6D).  Additionally, the effect of 
Notch inhibition on already differentiated Th17 cells was assessed. Naïve CD4
+
 T cells
were cultured in Th17 polarizing conditions for 4 days followed by treatment with 
either DMSO or GSI. Interestingly no changes in IL-17 levels were detected 
(Figure6E). 
3.3.2 The inhibition of gamma secretase during human Th17 polarization results in 
decreased Th17 associated cytokine levels 
To determine whether Notch signaling also plays a role in human Th17 differentiation, 
we treated in-vitro human Th17 polarized cells two different GSI (ILCHO and 
compound E). Naïve CD4
+
 T cells (CD4
+
CD45RA
+
) were purified from peripheral
blood mononuclear cells, pretreated with either GSI or DMSO for 30 min and cultured 
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in Th17 polarization conditions for 24, 48 and 72 h. IL-17A, IL-17 F and IL-22 secreted 
by human Th17 cells was significantly reduced in the presence of GSI compared to 
DMSO (Figure7A). Surprisingly we did not detect significant levels of IL-21 in human 
in-vitro differentiated Th17 cells (data not shown). Consistent with the murine data, 
Th17 polarization of human CD4
+
 T cells resulted in increased levels of activated 
Notch1, compared to those activated under neutral conditions (Figure7B). An MTS 
assay was performed to confirm the decrease in IL-17 secretion by GSI was not due to 
an effect on cell proliferation (data not shown). Next we assessed the effect of Notch 
inhibition in fully differentiated Th17 cells. Naïve CD4
+
 T cells were differentiated in 
Th17 conditions for 4 days followed by treatment with either DMSO or GSI. As seen in 
murine cells no change in IL-17 A and IL-22 cytokines were observed (Figure7C). 
Taken together, data in Figures 1 and 2 show that GSI treatment blocks the 
differentiation of naïve CD4+ T cells into Th17 cells.  Moreover treatment with GSI 
affects Th17 differentiation at earlier time points, but not in cells already committed to 
the Th17 lineage, suggesting a requirement for Notch signaling at early stages of Th17 
differentiation. 
3.3.3 Delivery of Notch1 siRNA to human naïve CD4
+
 T cells leads to decreased IL-
17 secretion 
GSI blocks targets of -secretase including all members of the Notch family of proteins. 
To determine whether Notch1 is a functional target of GSI during Th17 polarization, 
expression of Notch1 was reduced by delivery of siRNA to naïve CD4
+
T cells. Naïve 
CD4
+
 T cells were nucleoporated with Notch1 specific siRNA and subsequently 
polarized to the Th17 lineage and harvested 48 h after transfection. Western blot 
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analysis of Notch1 protein and quantitative RT-PCR confirmed that Notch1 siRNA 
reduced the expression of Notch1 protein (Figure8A). Western blot of Notch 2, 3 and 4 
was also performed to confirm the specificity of Notch1 siRNA . Notch1 knockdown 
significantly inhibited IL-17A and IL-17F production under Th17 polarizing conditions 
(Figure8B). Surprisingly we did not observe a significant reduction in IL-22 production 
upon Notch1 knockdown (Figure8B).  An MTS assay was performed to check whether 
the reduction in IL-17 in Notch1 siRNA-treated cells was due to differential cell 
survival revealed no change between scrambled siRNA and Notch1 siRNA. 
The role of Notch1 in Th17 differentiation was confirmed by over-expressing activated 
Notch1 (intracellular domain of Notch1 cloned in the LZRS retroviral construct) in 
naïve human CD4
+ 
T cells followed by Th17 polarization. An immunoblot for Notch1
confirmed over-expression (Figure8C). Naïve CD4
+
 T cells overexpressing Notch1
IC
LZRS produced higher levels of IL-17 compared to control cells (Figure 8D). 
Interestingly Notch1 overexpression also increased IL-17 secretion in cells activated 
under Th0 conditions. 
3.3.4 Notch1 binds to the ROR gamma T promoter 
The orphan nuclear receptor RORγt is a key transcription factor that regulates the 
differentiation of the Th17 effector cell lineage. Thus, we explored whether Notch may 
regulate its expression. RNA was isolated from mouse CD4
+
 T cells polarized under
Th17 conditions. cDNA was then synthesized to perform quantitative RT-PCR. RORγt 
mRNA expression was reduced by two-fold in Th17 polarized cells treated with GSI 
compared to DMSO-treated cells (Figure 9A). To determine whether Notch1 influences 
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human Th17 polarization by regulating RORγt expression, naïve human CD4+ T cells 
were purified, and nucleoporated with Notch1 specific siRNA, followed by culture 
under Th17 polarizing conditions. Quantitative RT-PCR of RORγt demonstrated that 
Notch1 knockdown resulted in decreased levels of RORγt transcripts (Figure 9B). 
Taken together, these data indicate that Notch1 regulates the expression of RORγt. 
We then explored the possibility that Notch1 may directly regulate the human RORγt 
promoter. Analysis of this promoter revealed two potential CSL sites within the 
proximal 3kb promoter upstream of the RORγt transcriptional start site (Figure9C). 
Chromatin immunoprecipitation analysis (ChIP) using an anti-Notch1 antibody was 
then performed to determine whether Notch1 binds directly to the RORγt promoter.  
The data presented in Figure 4D indicate that Notch1 binds directly to putative CSL 
binding sites in the human RORγt promoter (Figure9D).  In particular, Notch1 bound at 
the CSL1 site, which could be inhibited by treatment with GSI.  
3.3.5 Notch 1 regulates IL-17 promoter activity 
Since Notch has been reported to regulate and bind directly to the IFN-γ and IL-4 
promoters, it is possible that Notch may also regulate the IL-17 promoter in addition to 
the RORγt promoter.  Mouse CD4+ T cells were differentiated in-vitro towards the 
Th17 lineage in the presence of either DMSO or GSI. Transcript levels of IL-17 were 
reduced by 9 fold in GSI treated Th17 cells as detected by quantitative real time PCR 
(Figure9A), suggesting Notch may directly regulate IL-17 promoter. Further, co-
transfection of 293T cells with a human IL-17 promoter luciferase construct in 
combination with an activated Notch1 expression vector construct (N1
IC
) revealed that 
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Notch1 expression significantly increased IL-17 promoter activity (Figure 10A). This 
suggests that Notch1 regulates the IL-17 promoter. The human IL-17 promoter (3kb) 
upstream of the transcription start site (TSS) was therefore analyzed for putative CSL 
binding sites (Figure5B). We found four putative CSL sites within this region (Figure 
10B). ChIP analysis of cells polarized under Th17 conditions, showed that Notch1 binds 
to putative CSL binding sites in the human IL-17 promoter, particularly CSL1 and 4 
(Figure10C, 10D), but not CSL 2 and 3 (data not shown).  The binding was inhibited by 
the pretreatment with GSI (Figure10C). Thus Notch1 directly binds to both RORγt and 
IL-17 promoters and regulates Th17 differentiation. 
3.3.6 GSI ameliorates the severity of EAE–induced inflammation and Th17 
differentiation in-vivo 
In-vitro experiments demonstrate that reducing Notch activation causes a significant 
decrease in IL-17 levels. To investigate if the in-vitro observations seen could be 
replicated in an in-vivo setting, an EAE model was used in this study.  SJL/J mice were 
fed control chow or GSI (LY) chow. LY is an orally active GSI that is chemically 
similar to compound E. We have previously used LY incorporated into chow  in mouse 
models of immune disorders and determined that doses between 2.5 and 5 mg/kg/day 
are safe and effective in reducing Notch activity systemically. Higher doses cause the 
well-known secretory diarrhea due to goblet cell metaplasia of the intestine. We have 
previously reported that GSI treatment ameliorates EAE progression (8). However, the 
role of Th17 cells in this model was not understood at the time, and in that report we 
explored exclusively Th1 responses. To induce EAE, mice were treated with PLP 
peptide emulsified in CFA and injected with pertussis toxin. The initial signs of EAE 
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were observed eight days after immunization of the control group and ten days after 
immunization for the GSI treated group. At the peak of disease the clinical mean score 
for the control group was 2, while it was 0.8 for the GSI treated group (Figure11A). 
Therefore GSI treatment significantly delayed the disease progression as well as 
reduced the severity of EAE symptoms, as previously shown (Minter et al., 2005). 
To determine whether Th17 responses were affected by GSI in-vivo, IL-17 levels in 
supernatents of peptide-stimulated splenocytes cultured from GSI- or control- treated 
mice were measured by ELISA. The GSI treated group showed significantly lower IL-
17 levels than the control group (Figure11B). Similarly, supernatants obtained from 
mononuclear cells isolated from spinal cords showed lower IL-17 levels in the GSI-
treated mice than in the control group (Figure11C). We also detected lower levels of 
IFNγ in peptide-restimulated splenocytes from GSI fed mice as compared to control 
mice (Figure11D). To determine whether the effect of GSI mediated inhibition of IL-17 
cytokines in-vivo is due to overall decrease in T cells number rather than Th17 cell 
differentiation, we determined the number of CD4
+ 
and CD8
+ 
T cells in spinal cord 
infiltrates. We found there were no significant differences in the number of cells 
infiltrating the spinal cord between the GSI or control chow fed mice (Figure11E). 
Additionally, no significant differences in CD4
+
 and CD8
+
 cells were observed in the 
spleens of GSI-fed and control mice (data not shown).  Indeed, we have maintained 
animals on GSI chow for as long as 6 months and not observed differences in CD4
+
 or 
CD8
+
 cell numbers (data not shown).  This suggests that the decrease in IL-17 in the 
group of mice fed with GSI was not due to a difference in infiltrating cell numbers, but 
is more likely due to the effects of GSI on Th17 differentiation. Additionally, we 
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performed intracellular staining of IL-17 in CD4
+
 T cells of splenocytes treated in vivo 
and observed significant decrease in mean fluorescent intensity of IL-17 in GSI fed 
mice as compared with control mice (Figure11F). Interestingly, we did not observe a 
decrease in the percentage of CD4
+
 T cells producing IL-17, suggesting that inhibiting 
Notch signaling does not affect the number of CD4
+
 T cells producing IL-17 but rather 
their inherent ability to produce Th17 associated cytokines. 
 
3.4 Discussion 
In this study, we addressed the role of Notch signaling in the development of a Th17 
response in human and mouse CD4
+
 T cells.  We employed several strategies to 
investigate the function of Notch in driving a Th17 response. Our data demonstrates that 
treatment with GSI, compounds known to block -secretase function, also decreases 
Th17 differentiation and Th17 associated cytokines secretion. Additionally, we have 
shown that specific inhibition of Notch1 expression through the use of Notch1 siRNA 
abrogates IL-17 A and F production in polarized human Th17 cells. Surprisingly we do 
not observe a significant decrease in IL-22 cytokine levels upon Notch1 knockdown. 
Comparing our GSI data and specific Notch1 siRNA data, it may be possible that IL-22 
is regulated by other downstream targets of -secretase. Alternatively, IL-22 may be 
regulated by other Notch family members, particularly Notch 2 as reported before 
(Alam et al., 2010). We also provide further insights into the role of Notch in Th17 
induction by demonstrating that blockade of Notch, either through inhibition of -
secretase or through siRNA mediated knockdown, results in reduced expression of 
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RORt, the transcription factor known to be required for effective induction of Th17 
cells.  These data, coupled with experiments showing Notch1 binding to both the RORt 
and the IL-17 promoters, suggest that Notch1 directly regulates the development of the 
Th17 subset of cells, at least in part, through the regulation of these two promoters.  The 
biological consequences of Notch1 effects on Th17 development are highlighted in our 
in-vivo EAE experiments where GSI-mediated blockade of Notch activation results in 
reduced clinical disease as well as reduced levels of IL-17 produced by restimulated 
CD4
+
 T cells isolated from EAE-induced animals treated with GSI.  Taken together, 
these data provide compelling evidence for a key role for Notch signaling in the 
development of an effective in-vitro and in-vivo Th17 response. We have also provide 
evidence that Notch signaling plays a role in early stages of Th17 differentiation as 
blocking Notch after 4 days of activation has no significant effect on Th17 associated 
cytokines in both mouse and human cells. 
Notch1 has been implicated in the induction of both the Th1 and Th2 subsets of CD4
+
 T 
cells (Minter et al., 2005; Fang et al., 2007; Amsen et al., 2007. Amsen et al., 2004 
suggested that different Notch ligands expressed on APCs drive differing T cell 
responses In particular, this group provided evidence that DLL ligands preferentially 
drive a Th1 cell fate while Jagged ligands drive a Th2 fate. Lukacs and colleagues 
(Mukherjee et al., 2009) recently revisited and expanded this observation and 
determined that DLL4 expression is induced on APCs by pathogen-associated signals 
and this ligand promotes expression of RORc and expansion of Th17 CD4
+ 
T cells. The 
role of Notch signaling in mutually exclusive Th1, Th2 and Th17 differentiation may be 
mediated by different Notch ligands. Alternatively it may be due to upregulation of 
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different Notch family members or by differential expression of the same Notch paralog 
(with Notch1 being the most likely candidate). Notch signaling has been studied 
extensively but most experimental systems interrogate the conventional Notch signaling 
pathway, where activation of Notch leads to the production of intracellular Notch 
(NICD), which translocates to the nucleus and drives CSL-dependent transcription.  
More recent data indicate that activation of Notch also influences NF-B signaling 
(Shin et al., 2006; Bellavia et al., 2000) suggesting cross talk between these two 
signaling pathways in T cells. Additionally, evidence from several groups in a variety of 
vertebrate and invertebrate systems reveal a role for Notch in the cytosol and point 
toward a non-nuclear role for Notch in activation of cell survival pathways 
(Perumalsamy et al., 2009; Perumalsamy et al., 2010). Therefore it is possible that 
different ligands activate different Notch signaling pathways, which, in turn, drive 
different outcomes that influence T helper differentiation and development. For 
example, the number of NICD molecules generated after activation and/or the duration 
of activation may dictate whether the canonical pathway or combinations of nuclear and 
cytoplasmic pathways are activated. Further experimentation is required to test this 
hypothesis. 
In summary, in this report, we describe a role for Notch signaling in the development of 
both human and murine Th17 responses. A broad range of diseases require an active 
Th17 response, from multiple sclerosis to solid tumors. Our data suggest that Notch 
signaling inhibitors may act in-vivo at least by suppressing the Th17 response and may 
be useful in a variety of clinical situations where Th17 responses are required for 
disease pathogenesis.  
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FIGURE 6. GSIs significantly downregulate Th17-associated cytokine levels in 
murine Th17 in vitro polarization assays. 
 A, ELISA for IL-17A, IL-17F, and IL-21 in supernatants of activated CD4
+
 T cells from 
C57BL/6 mice. Cells were pretreated in vitro with GSI (25 mM IL-CHO and 4 mM 
compound E) or with 0.1% DMSO (as a vehicle control) before 24, 48, and 72 h culture 
in Th17 polarizing conditions. Cells were then lifted, recounted, and cultured overnight. 
B, Notch1 expression in cells pretreated with or without ILCHO was evaluated by 
immunoblotting using Abs that recognized the cleaved active Notch1 Ab specific for 
actin was used to control for loading. C, Evaluation of Notch1 expression in cells 
pretreated with or without IL-CHO by flowcytometry using Abs specific for CD4+ cells 
and Notch1IC. D, Intracellular staining of IL-17 and IFN- in Th17-differentiated cells 
treated with either DMSO or GSI. E, Naive CD4
+
 T cells were differentiated towards the 
Th17 subset for 4 d followed by treatment with either DMSO or GSI. Supernatants were 
collected after 24 h and IL-17A ELISA was performed. Data shown represent one of at 
least three independent experiments done in triplicates. *p # 0.05, **p # 0.001, ***p # 
0.0001. 
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FIGURE 7. GSIs significantly reduce Th17 cytokine levels in human in vitro Th17 
polarization assays.  
A, ELISA of IL-17A, IL-17F, and IL-22 in supernatants of Th17-polarized naive human 
CD4+ T cells treated with GSIs or DMSO as a vehicle control. Purified human CD4+ T 
cells were pretreated with GSIs (2 mM IL-CHO and 5 mM compound E) or DMSO as a 
vehicle control and then cultured in Th0 and Th17 polarizing conditions. Supernatants 
were collected at 24, 48, and 72 h and were analyzed for IL-17A, IL-17F, and IL-22. B, 
Whole-cell lysates were prepared from naive CD4+ T cells unstimulated (US) or 
differentiated under Th0 and Th17 conditions and immunoblotted for active Notch1IC. b-
actin was used to confirm equal loading. C,Naive CD4+ T cells were activated in vitro 
under Th17 polarizing conditions for 4 d, followed by treatment with either DMSO or 
GSI. Supernatants were collected after 24 h and IL-17A and IL-22 ELISAs were 
performed. Data shown are representative of three independent experiments done in 
triplicates. *p # 0.05, **p # 0.001. 
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FIGURE 8. Notch 1 controls human Th17 polarization. 
Purified human naïve CD4
+
 T cells (1 x 10
7
) were nucleoporated with Notch1-specific
siRNA or control siRNA. After transfection, the cells were cultured under Th17 skewing 
conditions and whole-cell lysates and cDNA were prepared. A, Immunoblot of Notch1 
expression and b-actin (loading control). B, ELISA of IL-17A, IL-17F, and IL-22 were 
performed on the supernatants of naïve CD4
+
 T cells nucleoporated with control siRNA
and Notch1 siRNA followed by in vitro Th17 polarization. C, Immunoblot of Notch1IC 
after transduction of naive human CD4
+
 T cells with Notch1IC LZRS followed by Th17
differentiation. D, ELISA of IL-17 performed after naive CD4+ T cells transduced with 
control LZRS and intercellular Notch LZRS followed by Th17 differentiation. The data 
are representative of three independent experiments done is triplicates. *p # 0.05. 
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FIGURE 9. Notch1 regulates RORt promoter activity.  
A, In vitro ILCHO treatment downregulates RORt and IL-17 mRNA expression. Total 
RNA was isolated from CD4+ T cells pretreated with 25 mM IL-CHO or DMSO as a 
vehicle control and cultured in Th17 polarizing conditions and analyzed by quantitative 
real-time PCR. B, Human naive CD4+ T cells (1 x 10
7
) were nucleoporated with Notch1-
specific siRNA or scrambled siRNA followed by in vitro Th17 polarization. Cells were 
harvested and RORt expression was determined by quantitative RT-PCR. Transcript 
abundance was normalized to 18S rRNA expression. C, Schematic representation of 
putative CSL binding sites in human RORt promoter. D, Specific primers were used to 
amplify putative CSL binding sites on human RORt promoter. A ChIP assay was 
performed to determine recruitment of Notch1 on RORt promoter. Data shown represent 
fold recruitment of Notch1 on CSL binding sites on human RORt promoter with respect 
to control IgG normalized with 1% input DNA. Semiquantitative PCR was also 
performed using 2 ml DNA eluates using specific primers against CSL sites in RORt 
promoter to confirm transcript size. Data represent mean 6 SD of three independent 
experiments done in triplicates. *p # 0.05, **p # 0.01. US, unstimulated 
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FIGURE 10. Notch1 regulates human IL-17 promoter activity. 
 A, HEK 293T cells were cotransfected with intracellular activated Notch expression 
vector construct (Notch1IC) along with a human IL-17 promoter construct cloned 
upstream of firefly luciferase gene. A luciferase assay was performed and data were 
normalized to Renilla luciferase depicted as relative luciferase units (RLU). B, Schematic 
representation of putative CSL binding sites in human IL-17 promoter. C, A ChIP assay 
was performed to determine the recruitment of Notch1 on human IL-17 promoter. Data 
shown represents fold recruitment of Notch1 on human IL-17 promoter with respect to 
isotype control IgG normalized to input DNA. Semiquantitative PCR was also performed 
(2 ml DNA eluates) using specific primers against different putative CSL binding sites in 
human IL- 17 promoter to confirm transcript size. Data shown represent the mean 6 SD 
of three independent experiments done in triplicates 
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FIGURE 11. GSI treatment reduces EAE-induced inflammation and the 
development of PLP139–151-specific Th17 responses. 
 A, Clinical scores of SJL/J mice given GSI formulated chow, at 2.5 mg/kg alternated 
with 5 mg/kg for 4 wk. Control mice were given regular chow (n = 5 mice/group). 
Results represent the mean disease score grouping each group. Splenocytes (B) and cells 
from the spinal cords (C) of EAE-induced mice were restimulated ex vivo with PLP139–
151 at increasing concentrations and cultured for 5 d. The restimulation supernatants 
were then analyzed for IL-17 by ELISA. D, ELISA of IFN-g was performed on PLP139–
151-restimulated splenocytes. E, Total spinal cord cells were stained with CD4 and CD8 
Abs and analyzed by flow cytometry. F, Intracellular staining of IL-17A in splenocytes of 
SJL/J mice fed with GSI or control chow. Data shown represent the mean fluorescence 
intensity of IL-17 in CD4+ T cells. 
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CHAPTER 4 
 
TH17 SIGNALING REQUIRES NOTCH3 AND IS CSL/RBP-JK INDEPENDENT. 
 
4.1 Introduction 
Th17 cells are a distinct lineage of CD4
+
 helper T cells that are characterized by the 
production of IL-17, IL-22 and IL-2I as well as the expression of the transcription factors 
RORt and RORα. Th17 cells play a role in the protection against extracellular bacteria 
and fungi. Notch is a type I transmembrane, heterodimeric cell surface receptor that is 
widely conserved among species. It is responsible for determining numerous cell fates 
and decisions (Osborne and Minter 2006, Amsen et al., 2009). In the immune system, 
Notch signaling is best characterized for its role in promoting T lineage commitment and 
maturation (Yuan et al., 2010). It has also been shown to regulate peripheral T cell 
responses, such as in Th1, Th17 and Treg cells (Minter et al., 200: Keerthivasan et al., 
2011: Samon et al., 2008). However, dysregulated signaling has also been implicated in a 
number of different human diseases such as   autoimmunity, neurodegeneration and 
cancer (Koch and Radtke, 2010).   
There are four members of the Notch family protein, Notch1, Notch 2, Notch 3, and 
Notch 4. Canonical Notch ligands are type I transmembrane proteins belonging to two 
related families, Delta-like (Dll) and Jagged (Delta and Serrate in Drosophila). Both 
families contain highly conserved N-terminal DSL (Delta/Serrate/Lag-2) domains and 
varying numbers of EGF repeats in their extracellular domains (Yuan et al., 2010). Notch 
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1 and Notch 2 are robust activators of target genes while Notch3 is a weak activator since 
it lacks a transactivation domain. Nevertheless, some target genes of N3 include 
traditional Notch targets such as Hes-1, and Notch 3 is actually considered to be a strong 
activator of Hey-1. Other Notch 3 targets include Pbx1, a proto-oncogene, recently 
identified in ovarian cancer that is essential for cell proliferation and tumorigenicity. 
Pbx1 expression is transcriptionally regulated by Notch3 activation, and Notch3/CSL 
protein complex directly binds to the Pbx1 promoter segment harboring the CSL binding 
sequence (Park et al., 2008). Cerebral Autosomal-Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL) is an inherited, dominant, 
late-onset syndrome that has been associated with mutations in Notch 3. Patients with 
CADASIL develop widespread arteriopathy that manifests itself most severely in brain 
vessels, eventually causing chronic ischemic degeneration of neurons and glia. 
Activation of canonical  Notch signaling requires interactions between a DSL ligand 
expressed on the surface of one cell (signal-sending cell) and a Notch receptor  expressed 
on the surface of an opposing cell (signal-receiving cell). Notch is presented to ligand as 
a heterodimer produced as a result of processing by a furin-like protease during transit to 
the plasma membrane. Ligand binding triggers additional proteolytic cleavages of Notch, 
first by A-Disintegrin-And-Metalloproteases (ADAM) within the juxtamembrane region 
followed by γ-secretase within the transmembrane domain resulting in the release of the 
Notch intracellular domain (NICD) from the membrane. NICD translocates to the nucleus 
where it directly interacts with the CSL (CBF1, Su (H), LAG1) transcription factor and 
recruits coactivators including Mastermind to turn on expression of Notch target genes. 
(D'souza 2008).  
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The term non-canonical Notch signaling was originally coined to describe signaling 
events that are Notch dependent but do not rely on CSL and was first observed in 
Drosophila using a genetic approach to examine the precise requirements of various 
components of the Notch signaling pathway (Minter and Osborne, unpublished data). In 
some instances it has become apparent that non-canonical Notch signaling may occur in 
the cytosol giving rise to the name non-canonical, non-nuclear Notch signaling (Minter 
and Osborne, unpublished data). Data from our lab also points to the existence of non-
canonical nuclear Notch signaling since Notch has been found to be associated with the 
NF-B proteins, p50 or c-rel (Shin et al., 2006). We still have much to learn concerning 
the role of non-canonical Notch signaling in T cell development and function. 
EAE is an autoimmune disease in mice, characterized by ascending paralysis and is used 
as a model to study Multiple Sclerosis (MS) in humans. It was previously thought to be 
completely mediated by Th1 cells and their signature cytokine, IFN-. But with the 
discovery of Th17 cells, it was found that IL-17 cytokines play an essential role in the 
pathogenesis of EAE. Consequently, EAE is considered to be a good model to study 
Th17 responses.  
We and others have shown that inhibiting Notch by the use of GSI causes a significant 
decrease in IL-17 levels produced from CD4
+
 T cells polarized to Th17 in vitro 
(Keerthivasan et al., 2011, Jurynczyk et al., 2008).Also, the use of GSI significantly 
improved clinical scores in an EAE model where it was shown that IL-17 levels were 
reduced compared to controls. GSI are non-selective Notch inhibitors, inhibiting Notch 1 
through Notch 4. We have recently shown that Notch 1 is essential for the regulation of 
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human Th17 cells and so we hypothesized that Notch1 is also responsible for the 
regulation of Th17 responses in mice. In this study, by using a conditional Notch 1 
knock-out mouse we have shown that there are no significant differences in IL-17 levels 
produced by Notch 1 knock-out and control Th17 polarized CD4
+
 T-cells. Similarly, in
an EAE model, clinical scores as well as IL-17 levels were similar between the Notch-1 
knock-outs as well as the controls. This led us to the conclusion that Notch 1 is not 
required for Th17 differentiation in the mouse. 
A previous report had showed that selective inhibition of Notch3, but not Notch1 
receptor, abrogated Th1 and Th17-type responses of PLP-reactive T cells (Jurynczyk et 
al., 2008). We therefore hypothesized that Notch3 could be the Notch family member 
responsible for the regulation of Th17 responses. In this study, we use Notch3 knockout 
mice to show that Notch 3 is the Notch family member that is essential for Th17 
differentiation. 
Since mouse models are used to study human diseases, it becomes essential to understand 
differences in physiology and biology of cells between man and mouse. Therapeutic 
targets have been identified in mice and used to devise therapies in humans, making it 
essential to highlight differences between them. We have previously shown that Notch1 
is responsible for Th17 differentiation in humans and in this study we provide evidence to 
show that Notch3 is responsible for regulating Th17 responses in mice. 
. 
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4.2 Materials and Methods 
 
4.2.1 Animals 
Notch1 conditional knock-out mice were obtained from our collaborator, Lisa Minter in 
Umass, Amherst. They obtained Notch1 conditional floxed mice by crossing Notch1 
fl/fl
 
(Notch1tm2Rko/GridJ) to MxCre
+/-
 (B6.Cg-Tg (Mx1-cre) 1Cgn/J) from Jackson 
Laboratory (Bar Harbor, ME.). Similarly, CSL knock-out mice were obtained by crossing 
homozygous CSL 
fl/fl 
females to MxCre
+/-
 male mice. The homozygous female CSL 
floxed mice were obtained from our collaborators in Mayo clinic. 
Notch3 knock-out spleens were kindly provided by Spyrros Artavanis-Tsakonas, Harvard 
University. Wild-type mice used as controls were C57B6 mice that are bred and kept in 
our mouse colonies at the University of Massachusetts, Amherst. All mice were housed 
in the Animal Care Facility at the University in accordance with the Institutional Animal 
Care and Use Committee guidelines. 
 
4.2.2 In Vivo Floxing of Notch-1 and CSL 
Notch1fl/fl x MxCre+/- mice and Notch1fl/fl x MxCre-/- mice were given 5 IP injections of 
Poly (I)-Poly(C), Amersham Biosciences (Piscataway, NJ), at a dose of 12-15 μg per 
gram of weight every other day. Notch1fl/fl x MxCre+/- control mice were given equal 
amounts of PBS vehicle. Mice were then rested for 3 weeks after the last injection before 
being used in experiments. 
4.2.3 Antibodies 
Anti-Notch 3 and anti-Notch 1 antibody were obtained from R&D systems.  
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4.2.4 Cell culture and in-vitro polarization 
For in-vitro polarization assays CD4 T cells were cultured and polarized according to 
Sheeret al., 2011.Briefly cells (2.5- 3 106/ml) were pretreated in vitro at 37°C for 30 min 
with 10mg/ml anti-Notch3  or with anti-Notch1 antibody and then plated onto 12- or 6-
well plates precoated with 1 mg/ml each anti-CD3 and anti-CD28. To polarize CD4+ T 
cells to a Th17 phenotype, 20 ng IL-6 (R&D Systems, Minneapolis,MN), 5 ng TGF-b 
(R&D Systems), and 10 mg both anti–IFN-g (BD Pharmingen) and anti–IL-4 (BD 
Pharmingen) were used per milliliter of cells . Cells were polarized for 24, 48, or 72 h. 
The activation supernatants were evaluated for IL-17A (BD Biosciences). 
 
4.2.5 Intracellular staining and cell surface staining 
Mouse CD4
+
 T cells were polarized toward a Th17 phenotype as described above. After 
72 h, the cells were stimulated by adding 80 nM PMA and 2.5mM ionomycin  in addition 
to brefeldin A for 5 h. Cells were fixed and permeabilized using the BD 
Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s instructions. 
Fluorescent Abs (anti-mouse CD4-FITC, anti-mouse IL-17A-allophycocyanin, and anti-
mouse IFN-g-PE) were obtained from BD Biosciences. Anti-mouse Notch1-PE was 
obtained from eBioscience. Cells were analyzed on a FACS LSR II (BD Biosciences). 
 
4.2.6 EAE evaluation 
EAE was induced by immunizing mice in the flank with 150 mg  MOG(Invitrogen, 
Carlsbad, CA) supplemented with 400 mg Mycobacterium tuberculosis H37RA (Difco, 
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Detroit, MI). Pertussis toxin (200 ng; Sigma-Aldrich) was injected i.p. on the day of 
immunization. The progression and severity of disease was monitored and scored from 0 
to 5 as follows: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 
4, hind limb and forelimb paralysis; 5, morbidity and death. Data are reported as the 
mean daily clinical score (42–44). Mice were anesthetized and perfused through the left 
cardiac ventricle with PBS during the peak of disease (day 15 post immunization). Spinal 
cords and spleens were removed by dissection. Splenocytes were cultured at 37°C with 
medium alone or with different concentrations of MOG Ag for 5 d. To prepare a single-
cell suspension, spinal cords were cut into pieces and the tissues were mashed and passed 
through a 70-mm mesh. Mononuclear cells were isolated over a Percoll gradient and were 
then cultured with MOG Ag for 5 d. IL-17 ELISAs were then performed on supernatants 
from all restimulated cells.  
 
4.3 Results 
 
4.3.1 Notch-sparing GSIs added during Th17 polarization, does not result in 
reduced IL-17 cytokine production 
GSIs have been widely used to block the Notch pathway by us (Keerthivasan et al., 2011) 
and others (Tsoa et al., 2009). One caveat when dealing with GSIs is the fact that they 
have multiple targets in addition to the enzyme gamma-secretase. GSIs are consistently 
used in Alzheimer disease studies since they prevent the cleavage of βAPP (β -amyloid 
precursor protein). The main histological hallmark of Alzheimer’s disease is the senile 
plaque, a proteinaceous deposit that is probably a result of exacerbated production of Aβ-
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related peptides derived from proteolytic cleavage of βAPP by β - and -secretases. It has 
been hypothesized that reducing the extent of secretase activity would diminish the whole 
Aβ load and hopefully benefit patients with Alzheimer’s disease.  But due to GSI 
inhibitors lack of -secretase substrate selectivity; GSI affect the cleavage of 
transmembrane proteins that include, amongst others, Notch, ErbB-4, nectin 1α, and E-
cadherin (Petit et al., 2001, 2003).Of specific importance is Notch, since its inhibition can 
cause severe side-effects in the recipients. Consequently, Alzheimer disease researchers 
have developed GSIs that do not inhibit Notch. JLK-6 (7-amino-4-chloro-3-
methoxyisocoumarin), is a GSI that does not inhibit Notch as well as α and- β secretases, 
the proteasome, or GSK3 β. 
In this study, we used JLK-6, a Notch sparing GSI and compared it to ILCHO, a regular 
GSI. Naive CD4
+
 T cells were isolated from spleens of 8- to 12-wk-old C57BL/6 mice, 
pretreated with GSI, JLK-6 or DMSO control for 30 min at 37°C and cultured in Th17 
polarizing conditions for 48, or 72 h. IL-17 cytokine levels were assessed at 48 h. The 
level of IL-17A produced by Th17 cells treated with JLK-6 was significantly increased in 
comparison with both ILCHO and control DMSO-treated Th17-polarized cells (Figure 
12A).Intracellular staining of Th17 cells polarized for 72 h showed the same trend, with  
JLK-6 treated cells producing more IL-17 than either ILCHO or DMSO treated 
cells(Figure 12B,C,D). We had hypothesized that no differences would be seen between 
Th17 polarized cells treated with JLK-6 or DMSO. Nevertheless, our data supports the 
notion that the decrease in IL-17 levels in Th17 polarized cells is due to inhibition of the 
Notch pathway. 
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4.3.2 Murine Th17 differentiation is Notch-1 independent 
Keerthivasan et al., 20011 showed that Notch 1 was essential in regulating human Th17 
cells. We hypothesized that Notch1 would also be the Notch family member regulating 
murine Th17 responses. Notch 1 is essential to the viability of organisms and therefore 
deleting Notch1 is embryonically lethal. To get around this issue, we used conditional 
Notch 1 knock-out mice. These conditional Notch1- knockout mice were generated using 
the Cre/loxP system, in which the gene of interest (Notch 1) is flanked by loxP sites 
(‘floxed’). The floxed sequence can be removed using Cre recombinase, which 
recognizes the loxP sites. The cre recombinase is produced upon activation of cre 
promoters by PolyIC injections. Although, we expected Notch 1 to be knocked out 
completely, we found that Notch1 was significantly reduced but not absent completely. 
 Naive CD4+ T cells were isolated from spleens of 8- to 12-wk-old of Mxcre positive 
mice (where Notch 1 is reduced and are hence to be referred to as Notch 1 knockouts) 
and Mxcre negative mice (where Notch 1 is intact and hence will be referred to as 
controls) Notch 1 knock-out mice cultured in Th17 polarizing conditions for 24 h. IL-17 
cytokine levels were assessed by ELISA. The level of IL-17 produced by Th17 cells from 
Notch 1 knockout mice was similar to control Th17-polarized cells (Figure 13A). To 
ensure that Notch1 was reduced in the knock-out mice, intracellular staining was carried 
out.Notch1 was found to be reduced in the Mxcre positive mice as compared to Mxcre 
negative mice (Figure 13B). We therefore concluded that Notch 1 is not the Notch family 
member responsible for murine Th17 differentiation. 
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To determine whether our in-vitro results would also be apparent in-vivo, EAE was 
induced in these mice. Since they are on a B6 background, MOG peptide was used to 
induce EAE.150ug of MOG peptide emulsified in CFA together with m.tuberculosis 
were subcutaneously injected on the side of each flank of Notch 1 knockout mice and 
controls. Pertusis toxin was injected inter peritonealy to open up the blood brain barrier. 
Clinical scores were recorded daily for each group of mice and it was noted that no 
differences in scores were seen between the Notch 1 knockouts and controls (Figure 
14A). Therefore, inhibiting Notch 1 does not reduce EAE inflammation.  
To determine whether Th17 responses were affected by reduction of Notch1 in vivo, IL-
17 levels in supernatants of peptide-stimulated splenocytes cultured from Notch 1 
knockouts or control-treated mice were measured by ELISA.  No significant differences 
were seen in IL-17 levels between the two groups (Figure 14B).These data led us to 
conclude that Notch 1 does not affect the severity of clinical symptoms in EAE nor does 
it affect the levels of IL-17, an essential cytokine in the pathogenesis of EAE. 
4.3.3 Notch 3 is the Notch family member responsible for regulating the 
differentiation of Th17 cells 
Based on observations made by Jurynczyk et al., 2008, we hypothesized that Notch3 may 
be responsible for Th17 regulation. We repeated these experiments where naive CD4+ T 
cells were isolated from spleens of 8- to 12-wk-old C57BL/6 mice, pretreated with anti-
Notch 3 antibody, anti-Notch 1 antibody, or DMSO control for 30 min at 37°C and 
cultured in Th17 polarizing conditions for 72 h. IL-17 cytokine levels were determined 
by ELISA. The level of IL-17 produced by Th17 cells treated with anti-Notch 3 
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antibodies was significantly decreased in comparison with control Th17-polarized cells 
(Figure 15). As we have shown previously, IL-17 levels produced by GSI- treated Th17 
cells were significantly decreased in comparison with control Th17-polarized cells while 
there were no significant differences in IL-17 levels between, anti-Notch 1 treated Th17 
cells and controls. 
Therefore, Notch 3 appears to be the Notch family member responsible for Th17 
differentiation. In order to more fully establish the role of Notch 3, we used spleens from 
Notch 3 knockout mice. Since Notch3 is not essential for survival, germline Notch 3 
knockouts can readily be achieved (Krebs et al., 2003). Naive CD4+ T cells were isolated 
from spleens of Notch 3 knockout mice and cultured in Th17 polarizing conditions for 72 
h. IL-17 cytokine levels were then determined by ELISA. The level of IL-17A produced 
by Th17 cells from Notch3 knockout cells was significantly decreased in comparison 
with control Th17-polarized cells (Figure 16A). This led to the conclusion that Notch 3 is 
responsible for regulating Th17 responses. We also examined lL-2 production in these 
knockouts (Figure 16B).One of the Notch3 knockout samples produced less IL-2 but we 
do not believe that this plays a role in the results seen.  
4.3.4 Notch signaling in Th17 cells proceeds through a non-canonical pathway 
Having examined canonical Notch signaling in Th17 cells, we were interested in asking 
whether non-canonical Notch signaling played a role in Th17 differentiation. To answer 
that question, we generated CSL knockout mice using the Cre/loxP system. Naive CD4
+ 
T cells were isolated from spleens of CSL knockout mice and cultured in Th17 polarizing 
conditions for 72 h. IL-17 cytokine levels were then determined by ELISA. The level of 
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IL-17A produced by Th17 cells from CSL knockout cells was increased in comparison 
with control Th17-polarized cells (Figure 17).This indicated that Notch regulates Th17 in 
a CSL independent manner. 
4.4 Discussion 
The role of Notch in the differentiation of Th17 cells and EAE has been reported by us as 
well as by others. Inhibiting the Notch pathway by the use of GSI causes a significant 
improvement in EAE symptoms. This is partly due to decreasing the production of IL-17 
and IFN from Th17 and Th1 cells respectively. (Sherr et al., 2011; Minter et al., 2005).  
secretase is a common target of pharmacological inhibition by molecules such as DAPT 
and ILCH0. Such -secretase inhibitors are powerful blockers of Notch activity, with the 
important caveat that the -secretase complex cleaves around ninety different proteins 
(Haapasalo and Kovacs et al., 2011). Thus, although γ‑secretase inhibitors may be a 
useful tool to screen for Notch pathway involvement, genetic approaches are necessary 
for more definitive conclusions regarding such involvement. Indeed, the lack of substrate 
specificity of γ‑secretase inhibitors and the concomitant challenges in interpreting clinical 
data have hampered progress in the field of Alzheimer’s disease therapeutics. In order to 
resolve this issue, we have used a GSI, JLK-6, which does not inhibit Notch. Since GSI 
are considered as potential therapeutics for Alzheimer’s disease, these Notch-sparing GSI 
were produced to circumvent the side-effects produced by inhibiting Notch. 
In this study we pre-incubated naiive CD4
+
 T cells with JLK-6 for thirty minutes before 
culturing them in Th17 polarization conditions. At 48h, supernatants were tested for IL-
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17 by ELISA and intracellular staining for IL-17 cells was carried out at 72h. In both 
cases there was a significant increase in IL-17 produced by JLK-6 treated cells compared 
to ILCHO treated cells and DMSO treated control cells. These results support the idea 
that the effects seen are due to Notch inhibition by GSI since we usually see a significant 
reduction in IL-17 levels in GSI treated cells. Nevertheless, these results can be 
controversial since an effect, even though it was a different effect, was seen when using 
the Notch-sparing GSI. 
In order to validate our results, we used conditional Notch 1 knockout mice, which utilize 
the Cre/loxP system. We did not see any differences in IL-17 production between Th17 
polarized CD4
+
T cells obtained from Notch 1 knockouts or controls. This was a
surprising result since we expected Notch 1 to be the Notch family member responsible 
for Th17 differentiation .We have previously reported that Notch1 is involved in human 
Th17 differentiation (Keerthivasan et al., 2011) and had hypothesized that Notch 1 would 
also be important in murine Th17 differentiation. 
 To ensure that our in-vitro data was physiologically relevant, we induced EAE in Notch 
1 knockout mice and controls. There were no differences in clinical scores or IL-17 levels 
between Notch1 KO and controls. These results clearly demonstrate that Notch 1 does 
not play a role in murine Th17 differentiation. Of interest, was the observation that non-
polarized naiive CD4
+
 T cells from these floxed mice secreted high levels of IL-17, at
almost twice the amount secreted by the corresponding wild-type non-polarized cells. 
Similarly, Th17 polarized CD4+ T cells from the floxed mice had more than twice the 
amount of Th17 than their corresponding Th17 controls. This indicates that the genetic 
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manipulation of these floxed mice causes an inflammatory response as suggested by the 
increased levels of IL-17. Consequently, it is imperative to use Mxcre negative mice 
instead of wild-type mice as controls for experiments using these floxed animals. 
It is important to bear in mind that redundancy exists between different family members 
of the Notch family. A recent study (Tacchini-Cottier et al., 2012) investigated the role of 
Notch in Th1 cell differentiation following parasite infection. Mice with T cell-specific 
gene ablation of N1, N2 or both (N1N2
CD4Cre
) were infected with the protozoan parasite, 
Leishmania major. N1N2
CD4Cre
 mice, on the C57BL/6 L. major-resistant genetic 
background, developed unhealing lesions and uncontrolled parasitemia whereas mice 
with single inactivation of N1 or N2 in their T cells were resistant to infection and 
developed a protective Th1 immune response. This showed that CD4
+
 T cell expression 
of N1 or N2 is redundant in driving Th1 differentiation. It would be interesting to see if 
deleting both Notch 1 and Notch2 could bring about different results in our Notch 1 
knockout studies. We hope to address this question in future studies. 
Recent data has suggested that selective inhibition of Notch3, but not Notch1, receptor 
abrogated proliferation and Th1 and Th17-type responses of PLP-reactive T cells. In this 
study, we asked whether this observation could be replicated in our in-vitro setting. Naïve 
CD4
+
 T cells, pretreated with GSI or blocking antibodies to Notch 1 or Notch 3 were 
cultured in Th17 polarizing conditions. Th17 cells treated with anti-Notch 1 antibody 
secreted significantly less IL-17 than Th17 cells treated with anti-Notch 1 antibody or 
Th17 controls. Furthermore, CD4+ T cells from splenocytes of Notch 3 knockout mice 
blocking, cultured similarly in Th17 polarizing conditions produced significantly less IL-
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17 than Th17controls.This result clearly demonstrates that Notch 3 is responsible for 
murine Th17 differentiation.  
To date, differences are known to exist between human and mouse Th17 differentiation. 
A good example is the generation of murine Th17 cells in-vitro, which requires the 
addition of TGF- β, IL-6, anti-IL-4 and anti-IFN-  to naiive CD4 + T cells. Of note is a 
recent study that has suggested that TGF-β is dispensable for the differentiation of murine 
Th17 cells and that its effect is mainly to neutralize the effects of IL-4 and IFN- which 
are known antagonists of IL-17. Nevertheless, TGF-β is still considered to be a necessary 
cytokine in murine Th17 polarization. Human Th17 cells are generated by the addition of 
IL-1 β, IL-6, anti-IL-4 and anti-IFN-  to naiive CD4 + T cells. TGF- β is absolutely not 
needed for IL-17 production in human T cells; in fact, TGF- β seems to inhibit IL-17 
production from activated human CD4+ T cells (Matsushita et al., 2008). It is therefore 
not completely surprising that different Notch members are responsible for the regulation 
of Th17 responses in humans and mice.  
Cannonical Notch signaling is signaling that ensues through the Notch core pathway, 
mainly that of the DSL-Notch-CSL-MAML axis. Any deviation from that core pathway 
is referred to as non-canonical Notch signaling but there is little data concerning this 
mode of signaling.  To investigate non-canonical Notch signaling, conditional 
CSL/RBPjK knockout mice using the Cre/loxP system were used.CD4
+
T cells isolated 
from splenocytes of CSL/RBPjK knockout and wild-type control mice were cultured in 
Th17 polarizing conditions. After 48 hours, IL-17 levels in supernatants were determined 
by ELISA. There were no differences in IL-17 levels between CSL/RBPjK and wild-type 
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controls. This indicates that Notch signaling on Th17 cells can proceed through a 
CSL/RBPjK independent pathway. It could be speculated that crosstalk between other 
signaling pathways could provide alternative proteins that could function in a CSL-
independent manner. Further studies are required to elucidate this signaling pathway.  
Our study highlights differences in the Notch members that regulate Th17 responses in 
humans versus mice. Th17 cytokines are important proinflammatory mediators that are 
thought to mediate several autoimmune diseases and Notch inhibitors are promising 
therapeutic targets. Therefore, it is imperative to fully understand the differences between 
disease pathogenesis in mice versus humans, thus enabling the accurate translation of any 
therapeutic benefits seen in mouse models. The discovery that Th17 signaling can ensue 
in a CSL/RBPjK independent manner, reveals the exciting possibility of regulating Th17 
responses via potential new targets that are waiting to be discovered. 
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Figure 12: Notch sparing GSI, unlike regular GSI, increases IL-17 production from 
Th17 polarized CD4 T cells. 
A, ELISA for IL-17 in supernatants of activated CD4+ T cells from C57BL/6 mice. Cells 
were pretreated in vitro with GSI (25 mM IL-CHO),JLK-6 (10 um) or with 0.1% DMSO 
(as a vehicle control) before 48 h culture in Th17 polarizing conditions,  Intracellular 
staining of IL-17 in Th17-differentiated cells treated with either B,DMSO;C ,JLK-6 or D, 
GSI . 
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Figure 13: IL-17 levels were similar in Notch 1 knock-out and control mice.  
A, ELISA for IL-17 in supernatants of activated CD4+ T cells from Notch 1 knock-out 
mice. Cells were cultured for 24 h in Th17 polarizing conditions. B, Intracellular staining 
of Notch 1 in Th17-differentiated cells showing that Notch1 was reduced in the knock-
outs. 
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Figure 14: EAE-induced inflammation and the development of MOG-specific Th17 
responses are not reduced in Notch 1 knock-out mice  
.A, Clinical scores of Notch 1 knock-out mice, (n = 5 mice/group). Results represent the 
mean disease score of each group. Splenocytes (B) of EAE-induced mice were 
restimulated ex vivo with MOG peptide at increasing concentrations and cultured for 5 d. 
The restimulation supernatants were then analyzed for IL-17 by ELISA. 
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Figure 15: Notch 3 blocking antibody significantly down regulates IL-17 cytokine 
levels in Th17 in vitro polarization assays.  
A, ELISA for IL-17 were performed in supernatants of activated CD4
+
 T cells from
C57BL/6 mice. Cells were preincubated in vitro with anti-Notch 3(10 uM/ml), anti-Notch 
1(10 uM/ml) and GSI (25 mM ILCHO) before 72 h culture in Th17 polarizing 
conditions. 
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Figure 16: IL-17 levels are significantly reduced in Notch 3 knock-out mice. 
A, ELISAs for IL-17 and B, IL-2 were performed in supernatants of activated CD4
+
 T
cells from Notch 3 knock-out mice. Cells were cultured for 72 h in Th17 polarizing 
conditions. 
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Figure 17: CSL knockouts produce significantly more IL-17 than controls. 
 ELISAs for IL-17 were performed in supernatants of activated CD4+ T cells from CSL 
knock-out mice. Cells were cultured for 48 h in Th17 polarizing conditions. 
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CHAPTER 5 
CONCLUDING REMARKS 
Cells need to sense cues from their extracellular environment and integrate this 
information into appropriate developmental or physiological responses. Although there 
are a number of mechanisms that relay information from the exterior of the cell to the 
interior, a relatively small set of highly evolutionarily conserved signaling pathways 
stand out as playing particularly crucial roles in this transmission of information. In this 
roster of ‘elite’ intracellular signaling mechanisms lies the Notch signaling pathway 
(Andersson et al., 2011). 
The Notch signaling pathway is one of the most important pathways during 
developmental processes. In the adult system it is of great significance for different 
biological processes such as the maintenance of stem cells or in angiogenic processes. 
Further, dysregulation of Notch has been observed in many types of diseases ranging 
from developmental disorders, autoimmunity and numerous cancer types (Dickic et al., 
2010). 
Our understanding of T-cell differentiation has grown enormously in the past two 
decades. Since the discovery by Mossman and Coffman that CD4
+
T cells can be divided
into Th1 and Th2 according to the cytokines they secrete, several more classes of T 
helper cells have been described. These classes include T-regs, Th17, Th9, Th22 and Tfh. 
The branch of Th cell that is activated dictates the type of immune response that is 
mounted by the body. So, for example Th1 activates a cell- mediated immune response to 
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protect against intracellular organisms whilst Th2 activates a humoral- mediated immune 
response that protects against extracellular organisms. Unfortunately, Th immune 
responses can sometimes go awry and cause substantial damage to the very host they are 
supposedly protecting. Thus, Th1 and Th17 responses may cause autoimmunity whilst 
Th2 response may cause asthma and allergy. Hence, it becomes vital to understand 
mechanisms by which these Th cells can be harnessed and regulated. 
Previous work done by our group has shown that Notch can regulate Th1 and Treg 
responses as well as affect proliferation of T cells (Minter et al., 2005; Samon et al., 
2008). In this current study, we demonstrate that Notch, specifically Notch3, can regulate 
Th17 responses. Using GSI and Notch 3 knockout mice, we show that inhibiting Notch 
causes a significant decrease in in-vitro IL-17 production from Th17 cells. Furthermore, 
inhibiting Notch by the use of GSI significantly alleviates clinical scores in an EAE 
model and that can be partially attributed to a decrease in Th17 and Th1 responses. These 
studies and several others have highlighted the importance of Notch-inhibiting 
compounds as attractive therapeutic agents. 
GSIs that block Notch proteolysis have long been used in the laboratory to inhibit Notch 
and are now being applied in clinical trials on cancer patients. In general, such inhibitors 
may show a broad range of side effects due to their low specificity (Dickic et al., 2010 ). 
γ-secretase inhibitors cause severe intestinal secretory metaplasia as a result of a marked 
increase in goblet cell differentiation and arrested cell proliferation in the intestinal 
crypts.( Grosveld 2009). Clearly, selective and specific inhibitors of Notch receptors or 
ligands are needed. 
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It is still not understood exactly how Notch signaling can generate appropriate signaling 
outputs in a variety of cellular contexts. It is also puzzling how one signaling pathway 
seems to regulate opposing mechanisms. For example, Notch down regulates or inhibits 
both the Th17 and T-reg responses, even though Th17 cells are proinflammatory whilst 
T-regs are antinflammatory. Similarly, Notch signaling has mostly been implicated in 
oncogenic effects with the exception of epidermal keratinocytes, where Notch1 acts as a 
tumour suppressor by impacting the stromal microenvironment (Dikic et al., 2010). This 
example highlights the importance of context in regard to signaling, thus Notch may 
affect certain mechanisms in some tissues but not in others. Notch1 and 2 contain a 
transactivation domain, a region which contains phosphorylation sites that may allow 
other signaling pathways to selectively modulate Notch activity.  
A conspicuous feature of the core canonical Notch pathway is the lack of an amplification 
step during signal transduction. Each activated Notch receptor molecule is consumed 
during signaling, yielding one NICD, suggesting that Notch signaling exhibits a 
stoichiometric relationship between signaling input and output and that signaling strength 
is important for generating the appropriate cellular response. Indeed, the Notch pathway 
is very sensitive to gene dosage deviations. In human, haploinsufficiency of Notch2 or 
Jagged 1 (JAG1), which encodes a Notch ligand, is observed in Alagille syndrome 
(McDaniell et al., 2006), a broad-spectrum syndrome characterized by liver, heart and 
eye defects as well as vertebral malformations (Alagille et al.,1987; Alagille et al., 1975), 
and Notch1 haploinsufficiency is also seen in aortic valve disease (Garg et al., 2006). 
Thus, signal strength, whether it means the number of ligand-receptor interactions on a 
cell or gene aberrations maybe responsible for the type of response elicited.  
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The relative strength of receptor-ligand interactions can also be modulated by post-
translational modifications of Notch receptors. The extracellular epidermal growth factor 
(EGF) repeats of Notch receptors can be modified by O-glucose or O-fucose additions, 
which are then subject to further modification (Stanley and Okajima, 2010). The addition 
of O-fucose to Notch receptors by protein O-fucosyltransferase 1 (Pofut1), is necessary 
for the subsequent glycosylation of Notch receptors by Fringe proteins (such as lunatic 
fringe, manic fringe and radical fringe in mammals) (Okajima et al., 2008). Fringe 
proteins can then add N-acetylglucosamine (GlcNAc) sugars to the O-fucose moiety. 
This glycosylation modulates the relative response of Notch receptors to ligands of the 
Delta versus Jagged/Serrate classes: Fringe potentiates interactions with Dll1 and reduces 
responsiveness to Jag1 (Hicks et al., 2000; Kato et al., 2010). The Fringe-mediated 
transcriptional changes reported thus far appear to be quantitative rather than qualitative 
in nature, i.e. the level of expression of the same set of downstream genes is modulated 
but the set of downstream genes that is activated or repressed is not. In most cellular 
contexts, ligands are not uniquely expressed on the signal-sending cell and, vice versa, 
receptors are not expressed only on the signal-receiving cell. Directionality of Notch 
signaling stems, at least in part, from the fact that ligands activate receptors on contacting 
cells (trans-activation), but generally inhibit receptors expressed in the same cell (cis-
inhibition) (de Celis and Bray, 1997). Cis-inhibition has at times been reported to lead to 
a downregulation of Notch receptor at the cell surface, as well as to a cell-autonomous 
downregulation of Notch target genes. 
It also appears that a specific course of T cell differentiation can be dictated depending 
upon what ligands on DCs (delta-like or jagged) are used to engage Notch receptors on T 
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cells during activation (Mukherjee et al., 2009). Dll3 might serve exclusively as a cis-
inhibiting ligand, as it is incapable of activating receptors in trans (Ladi et al., 2005). In 
addition, a multitude of non-canonical ligands can activate or inhibit Notch signaling. 
Therefore, there are multiple mechanisms that fine-tune and regulate Notch signaling, 
some of which are still undiscovered. This versatility and diversity in signaling helps 
explain how a single pathway could affect so many biological processes in different 
tissues.  
Non canonical Notch signaling differs from canonical signaling in that it can be initiated 
by a non-canonical ligand, or may not require cleavage of the Notch receptor. 
Alternatively, in some forms of non-canonical signaling there is no involvement of CSL, 
which may reflect interactions with other signaling pathways upstream of the Notch ICD-
CSL interaction. We have shown that Notch signaling in Th17 cells can proceed in a CSL 
independent manner. There is very little data concerning non-canonical signaling and 
much work remains to be done. Nevertheless, this is an exciting finding that could 
possibly highlight redundancy between the two pathways and potentially provide extra 
therapeutic targets for regulating Notch.  
Our studies demonstrate an important role for Notch in the regulation of Th17 signaling. 
This discovery is of two-fold importance. First, Th17 cells and their products are 
mediators of many autoimmune diseases such as MS and RA. Consequently, it is possible 
that regulating Th17 responses by targeting Notch may provide a way to control these 
responses and improve disease outcome. Indeed, we and others have shown this to be the 
case where inhibiting Notch in an EAE model, significantly improved clinical symptoms 
and down regulated Th17 responses (Keerthivasan et al., 2011, Jurynczyk et al., 2008). 
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 Secondly, Notch signaling dysregulation has been implicated in a great many adult 
human diseases ranging from cancer to neurodegeneration. Notch is therefore an 
important therapeutic target and it is currently being tested in clinical trials. It is therefore 
essential to understand how Notch manipulation may affect other immune mechanisms 
and cell types, thus avoiding potentially damaging side-effects.   
. 
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